View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 29, 2019	Apr. 12, 2019
Document And Entity Information [Abstract]
Document type	10-Q
Amendment flag	false
Document period end date	Mar. 29, 2019
Document fiscal year focus	2019
Document fiscal period focus	Q1
Current fiscal year end date	--12-31
Trading symbol	dhr
Entity registrant name	DANAHER CORP /DE/
Entity central index key	0000313616
Entity filer category	Large Accelerated Filer
Entity small business	false
Entity emerging growth company	false
Entity common stock, shares outstanding		715,933,649

Consolidated Condensed Balance Sheets - USD ($) $ in Millions	Mar. 29, 2019	Dec. 31, 2018
Current assets:
Cash and equivalents	$ 3,910.0	$ 787.8
Trade accounts receivable, net	3,409.2	3,489.6
Inventories:
Finished goods	1,098.4	1,031.2
Work in process	335.5	313.9
Raw materials	594.0	565.0
Total inventories	2,027.9	1,910.1
Prepaid expenses and other current assets	733.3	906.3
Total current assets	10,080.4	7,093.8
Property, plant and equipment, net of accumulated depreciation of $2,906.2 and $2,828.3, respectively	2,504.3	2,511.2
Other long-term assets	1,646.4	648.4
Goodwill	26,001.4	25,906.0
Other intangible assets, net	11,541.9	11,673.1
Total assets	51,774.4	47,832.5
Current liabilities:
Notes payable and current portion of long-term debt	36.6	51.8
Trade accounts payable	1,676.2	1,712.8
Accrued expenses and other liabilities	2,920.0	3,076.9
Total current liabilities	4,632.8	4,841.5
Other long-term liabilities	6,114.7	5,075.8
Long-term debt	9,458.2	9,688.5
Stockholders’ equity:
Preferred stock, without par value, 15.0 million shares authorized; 1.65 million shares of 4.75% Mandatory Convertible Preferred Stock, Series A, issued and outstanding at March 29, 2019; no shares issued or outstanding at December 31, 2018	1,599.6	0.0
Common stock - $0.01 par value, 2.0 billion shares authorized; 832.5 and 817.9 issued; 715.8 and 701.5 outstanding, respectively	8.3	8.2
Additional paid-in capital	7,376.3	5,834.3
Retained earnings	25,368.5	25,163.0
Accumulated other comprehensive income (loss)	(2,796.1)	(2,791.1)
Total Danaher stockholders’ equity	31,556.6	28,214.4
Noncontrolling interests	12.1	12.3
Total stockholders’ equity	31,568.7	28,226.7
Total liabilities and stockholders’ equity	$ 51,774.4	$ 47,832.5

Consolidated Condensed Balance Sheets Consolidated Condensed Balance Sheets (Parenthetical) - USD ($) shares in Thousands, $ in Millions	3 Months Ended
	Mar. 29, 2019	Dec. 31, 2018
Property, plant and equipment, net of accumulated depreciation	$ 2,906.2	$ 2,828.3
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	2,000,000	2,000,000
Common stock, shares issued	832,500	817,900
Common stock, shares outstanding	715,800	701,500
Convertible preferred stock
Preferred stock, dividend rate, percent	4.75%
Preferred stock, no par value	$ 0	$ 0
Preferred stock, shares authorized	15,000	0
Preferred stock, shares issued	1,650	0
Preferred stock, shares outstanding	1,650	0

Consolidated Condensed Statements Of Earnings - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 29, 2019	Mar. 30, 2018
Income Statement [Abstract]
Sales	$ 4,879.9	$ 4,695.4
Cost of sales	(2,161.9)	(2,051.8)
Gross profit	2,718.0	2,643.6
Operating costs:
Selling, general and administrative expenses	(1,683.4)	(1,601.9)
Research and development expenses	(310.8)	(298.7)
Operating profit	723.8	743.0
Nonoperating income (expense):
Other income, net	5.2	7.8
Interest expense	(23.3)	(39.1)
Interest income	15.7	1.4
Earnings before income taxes	721.4	713.1
Income taxes	(387.6)	(146.5)
Net earnings	333.8	566.6
Mandatory convertible preferred stock dividends	(6.5)	0.0
Net earnings attributable to common stockholders	$ 327.3	$ 566.6
Net earnings per common share:
Basic	$ 0.46	$ 0.81
Diluted	$ 0.46	$ 0.80
Average common stock and common equivalent shares outstanding:
Basic	707.6	698.6
Diluted	718.5	709.5

Consolidated Condensed Statements Of Comprehensive Income - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2019	Mar. 30, 2018
Statement of Comprehensive Income [Abstract]
Net earnings	$ 333.8	$ 566.6
Other comprehensive income (loss), net of income taxes:
Foreign currency translation adjustments	(10.8)	294.1
Pension and postretirement plan benefit adjustments	5.4	7.1
Unrealized gain (loss) on available-for-sale securities adjustments	0.4	(0.5)
Total other comprehensive income (loss), net of income taxes	(5.0)	300.7
Comprehensive income	$ 328.8	$ 867.3

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Consolidated Condensed Statement Of Stockholders' Equity - USD ($) shares in Millions, $ in Millions	Total	Common Stock	Preferred stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interests
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Adoption of accounting standards					$ 154.5	$ (151.2)
Adjusted balance, January 1, 2018, amount		$ 8.1	$ 0.0	$ 5,538.2	22,960.6	(2,145.4)	$ 9.6
Balance, shares at Dec. 31, 2017		812.5	0.0
Balance, amount at Dec. 31, 2017		$ 8.1	$ 0.0	5,538.2	22,806.1	(1,994.2)	9.6
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	$ 566.6				566.6
Other comprehensive income (loss)	300.7					300.7
Dividends declared					(111.8)
Common stock-based award activity, shares		1.9
Common stock-based award activity, amount				61.0
Common stock issued in connection with LYONs’ conversions, shares		0.4
Common stock issued in connection with LYONs’ conversions, amount				11.9
Change in noncontrolling interests							2.3
Balance, shares at Mar. 30, 2018		814.8	0.0
Balance, amount at Mar. 30, 2018		$ 8.1	$ 0.0	5,611.1	23,415.4	(1,844.7)	11.9
Balance, shares at Dec. 31, 2018		817.9	0.0
Balance, amount at Dec. 31, 2018	28,226.7	$ 8.2	$ 0.0	5,834.3	25,163.0	(2,791.1)	12.3
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	333.8				333.8
Other comprehensive income (loss)	(5.0)					(5.0)
Dividends declared					(121.8)
Mandatory convertible preferred stock cumulative dividends					(6.5)
Common stock-based award activity, shares		2.0
Common stock-based award activity, amount		$ 0.0		82.1
Common stock issued in connection with LYONs’ conversions, shares		0.5
Common stock issued in connection with LYONs’ conversions, amount				16.8
Issuance of stock, shares		12.1	1.7
Issuance of stock, amount		$ 0.1	$ 1,599.6	1,443.1
Change in noncontrolling interests							(0.2)
Balance, shares at Mar. 29, 2019		832.5	1.7
Balance, amount at Mar. 29, 2019	$ 31,568.7	$ 8.3	$ 1,599.6	$ 7,376.3	$ 25,368.5	$ (2,796.1)	$ 12.1

Consolidated Condensed Statement Of Stockholders' Equity Consolidated Condensed Statement Of Stockholders' Equity (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2019	Mar. 30, 2018
Statement of Stockholders' Equity [Abstract]
Debt conversion, converted instrument, tax benefit	$ 4.7	$ 3.1

Consolidated Condensed Statements Of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2019	Mar. 30, 2018
Cash flows from operating activities:
Net earnings	$ 333.8	$ 566.6
Noncash items:
Depreciation	148.5	148.5
Amortization	179.9	172.3
Stock-based compensation expense	39.2	33.3
Change in trade accounts receivable, net	73.8	219.0
Change in inventories	(132.3)	(128.9)
Change in trade accounts payable	(32.3)	51.4
Change in prepaid expenses and other assets	152.6	125.0
Change in accrued expenses and other liabilities	(59.9)	(358.3)
Net operating cash provided by operating activities	703.3	828.9
Cash flows from investing activities:
Cash paid for acquisitions	(308.2)	0.0
Payments for additions to property, plant and equipment	(155.7)	(137.9)
Proceeds from sales of property, plant and equipment	0.8	0.4
Payments for purchases of investments	(43.2)	0.0
Proceeds from sale of investments	0.0	21.9
All other investing activities	7.8	(7.1)
Net operating cash used in investing activities	(498.5)	(122.7)
Cash flows from financing activities:
Proceeds from the issuance of common stock in connection with stock-based compensation	37.3	23.2
Proceeds from the public offering of common stock, net of issuance costs	1,443.2	0.0
Proceeds from the public offering of preferred stock, net of issuance costs	1,599.6	0.0
Payment of dividends	(112.2)	(97.5)
Net repayments of borrowings (maturities of 90 days or less)	(86.1)	(236.6)
All other financing activities	(4.0)	(10.8)
Net operating cash provided by (used in) financing activities	2,877.8	(321.7)
Effect of exchange rate changes on cash and equivalents	39.6	30.9
Net change in cash and equivalents	3,122.2	415.4
Beginning balance of cash and equivalents	787.8	630.3
Ending balance of cash and equivalents	3,910.0	1,045.7
Supplemental disclosures:
Cash interest payments	42.0	47.7
Cash income tax (refunds) payments	$ (6.3)	$ 133.5

General

3 Months Ended

Mar. 29, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

General

GENERAL

The Consolidated Condensed Financial Statements included herein have been prepared by Danaher Corporation (“Danaher” or the “Company”) without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). In this quarterly report, the terms “Danaher” or the “Company” refer to Danaher Corporation, Danaher Corporation and its consolidated subsidiaries or the consolidated subsidiaries of Danaher Corporation, as the context requires. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to SEC rules and regulations; however, the Company believes that the disclosures are adequate to make the information presented not misleading. The Consolidated Condensed Financial Statements included herein should be read in conjunction with the financial statements as of and for the year ended December 31, 2018 and the Notes thereto included in the Company’s 2018 Annual Report on Form 10-K filed on February 21, 2019 (the “2018 Annual Report on Form 10-K”).

In the opinion of the Company, the accompanying financial statements contain all adjustments (consisting of only normal recurring accruals) necessary to present fairly the financial position of the Company as of March 29, 2019 and December 31, 2018, its results of operations for the three-month periods ended March 29, 2019 and March 30, 2018 and its cash flows for each of the three-month periods then ended.

Accounting Standards Recently Adopted

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), which requires lessees to recognize a right-of-use (“ROU”) asset and a lease liability for all leases with terms greater than 12 months and also requires disclosures by lessees and lessors about the amount, timing and uncertainty of cash flows arising from leases. The accounting applied by a lessor is largely unchanged from that applied under the prior standard. Subsequent to the issuance of Topic 842, the FASB clarified the guidance through several ASUs; hereinafter the collection of lease guidance is referred to as “ASC 842”.

On January 1, 2019, the Company adopted ASC 842 using the modified retrospective method for all lease arrangements at the beginning of the period of adoption. Results for reporting periods beginning January 1, 2019 are presented under ASC 842, while prior period amounts were not adjusted and continue to be reported in accordance with the Company’s historic accounting under ASC 840, Leases. The standard had a material impact on the Company’s Consolidated Condensed Balance Sheet but did not have a significant impact on the Company’s consolidated net earnings and cash flows. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases, while the accounting for finance leases remained substantially unchanged. For leases that commenced before the effective date of ASC 842, the Company elected the permitted practical expedients to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases. The Company also elected to include leases with a term of 12 months or less in the recognized ROU assets and lease liabilities.

As a result of the cumulative impact of adopting ASC 842, the Company recorded operating lease ROU assets of $971 million and operating lease liabilities of $1,012 million as of January 1, 2019, primarily related to real estate and automobile leases, based on the present value of the future lease payments on the date of adoption. Refer to Note 5 for the additional disclosures required by ASC 842.

The Company determines if an arrangement is a lease at inception. For leases where the Company is the lessee, ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also consists of any prepaid lease payments, lease incentives received, costs which will be incurred in exiting a lease and the amount of any asset or liability recognized on business combinations relating to favorable or unfavorable lease terms. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. The Company has lease agreements which require payments for lease and non-lease components and has elected to account for these as a single lease component.

The Company leases Life Sciences, Diagnostics, and Environmental & Applied Solutions equipment to customers in both operating-type lease (“OTL”) and sales-type lease (“STL”) arrangements. Equipment lease revenue for OTL agreements is recognized on a straight-line basis over the life of the lease, and the costs of customer-leased equipment is recorded within property, plant and equipment, net in the accompanying Consolidated Condensed Balance Sheets and depreciated over the equipment’s estimated useful life. Depreciation expense associated with the leased equipment under OTL arrangements is reflected in cost of sales in the accompanying Consolidated Condensed Statements of Earnings. The OTLs are generally not cancellable until after an initial term and may or may not require the customer to purchase a minimum number of consumables or tests throughout the contract term. Certain of the Company’s lease contracts are customized for larger customers and often result in complex terms and conditions that typically require significant judgment in applying the criteria used to evaluate whether the arrangement should be considered an OTL or an STL. An STL results in earlier recognition of equipment revenue as compared to an OTL. Some of the Company’s leases include a purchase option for the customer to purchase the leased asset at the end of the lease arrangement for a purchase price equal to the asset’s fair market value at the time of the purchase. The Company manages its risk on the unguaranteed residual asset for leased equipment through the pricing and term of the leases. In certain geographies, equipment coming off OTL and STL arrangements after the initial lease term may be leased to other customers or used for spare parts.

For lease arrangements with lease and non-lease components where the Company is the lessor, the Company allocates the contract’s transaction price to the lease and non-lease components on a relative standalone selling price basis using the Company’s best estimate of the standalone selling price of each distinct product or service in the contract. The primary method used to estimate standalone selling price is the price observed in standalone sales to customers; however, when prices in standalone sales are not available the Company may use third-party pricing for similar products or services or estimate the standalone selling price. Allocation of the transaction price is determined at the inception of the lease arrangement. The Company’s leases primarily consist of leases with fixed lease payments. For those leases with variable lease payments, the variable lease payment is typically based upon use of the leased equipment or the purchase of consumables used with the leased equipment.

In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which expands and refines hedge accounting for both financial and non-financial risk components, aligns the recognition and presentation of the effects of hedging instruments and hedge items in the financial statements and includes certain targeted improvements to ease the application of current guidance related to the assessment of hedge effectiveness. The ASU is effective for public entities for fiscal years beginning after December 15, 2018. In January 2019, the Company entered into approximately $1.9 billion of cross-currency swap derivative contracts to hedge its net investment in foreign operations against adverse changes in the exchange rates between the U.S. dollar and the Danish kroner, Japanese yen, euro and the Swiss franc. Refer to Note 9 for additional disclosures about the Company’s hedging activities.

Except for the above accounting policy for leases that was updated as a result of adopting ASC 842, there have been no changes to the Company’s significant accounting policies described in the Annual Report on Form 10-K for the year ended December 31, 2018 that have a material impact on the Company’s Consolidated Condensed Financial Statements and the related Notes.

Accounting Standards Not Yet Adopted

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. The ASU is effective for public entities for fiscal years beginning after December 15, 2019, with early adoption permitted. In November 2018, the FASB issued ASU No. 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses, which provided additional implementation guidance on the previously issued ASU. Management has not yet completed its assessment of the impact of the new standard on the Company’s Consolidated Financial Statements. Currently, the Company believes that the most notable impact of this ASU will relate to its processes around the assessment of the adequacy of its allowance for doubtful accounts on trade accounts receivable and the recognition of credit losses.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820), which modifies the disclosures on fair value measurements by removing the requirement to disclose the amount and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy and the policy for timing of such transfers. The ASU expands the disclosure requirements for Level 3 fair value measurements, primarily focused on changes in unrealized gains and losses included in other comprehensive income (loss). The ASU is effective for public entities for fiscal years beginning after December 15, 2019, with early adoption permitted. Management has not yet completed its assessment of the impact of the new standard on the Company’s financial statements.

In August 2018, the FASB issued ASU No. 2018-14, Disclosure Framework—Changes to the Disclosure Requirements for Defined Benefit Plans, which amends ASC 715 to add, remove, and clarify disclosure requirements related to defined benefit pension and other postretirement plans. The ASU is effective for public entities for fiscal years beginning after December 15, 2020, with early adoption permitted. Management has not yet completed its assessment of the impact of the new standard on the Company’s financial statements.

Accumulated Other Comprehensive Income (Loss)—Accumulated other comprehensive income (loss) refers to certain gains and losses that under U.S. GAAP are included in comprehensive income (loss) but are excluded from net earnings as these amounts are initially recorded as an adjustment to stockholders’ equity. The changes in accumulated other comprehensive income (loss) by component are summarized below ($ in millions). Foreign currency translation adjustments generally relate to indefinite investments in non-U.S. subsidiaries, as well as the impact from the Company’s hedges of its net investment in foreign operations, including the Company’s cross-currency swap derivatives, net of any tax impacts.



	Foreign Currency Translation Adjustments			Pension & Postretirement Plan Benefit Adjustments				Unrealized Gain (Loss) on Available-For-Sale Securities Adjustments			Total
For the Three-Month Period Ended March 29, 2019:
Balance, December 31, 2018	$	(2,098.1	)	$	(691.1	)		$	(1.9	)	$	(2,791.1	)
Other comprehensive income (loss) before reclassifications:
(Decrease) increase	(7.3		)	—				0.5			(6.8		)
Income tax impact	(3.5		)	—				(0.1		)	(3.6		)
Other comprehensive income (loss) before reclassifications, net of income taxes	(10.8		)	—				0.4			(10.4		)
Amounts reclassified from accumulated other comprehensive income (loss):
Increase	—			7.1			(a)	—			7.1
Income tax impact	—			(1.7		)		—			(1.7		)
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes	—			5.4				—			5.4
Net current period other comprehensive income (loss), net of income taxes	(10.8		)	5.4				0.4			(5.0		)
Balance, March 29, 2019	$	(2,108.9	)	$	(685.7	)		$	(1.5	)	$	(2,796.1	)
For the Three-Month Period Ended March 30, 2018:
Balance, December 31, 2017	$	(1,422.1	)	$	(571.2	)		$	(0.9	)	$	(1,994.2	)
Adoption of accounting standards	(43.8		)	(107.2		)		(0.2		)	(151.2		)
Balance, January 1, 2018	(1,465.9		)	(678.4		)		(1.1		)	(2,145.4		)
Other comprehensive income (loss) before reclassifications:
Increase (decrease)	294.1			—				(0.8		)	293.3
Income tax impact	—			—				0.3			0.3
Other comprehensive income (loss) before reclassifications, net of income taxes	294.1			—				(0.5		)	293.6
Amounts reclassified from accumulated other comprehensive income (loss):
Increase	—			9.3			(a)	—			9.3
Income tax impact	—			(2.2		)		—			(2.2		)
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes	—			7.1				—			7.1
Net current period other comprehensive income (loss), net of income taxes	294.1			7.1				(0.5		)	300.7
Balance, March 30, 2018	$	(1,171.8	)	$	(671.3	)		$	(1.6	)	$	(1,844.7	)

^(a) This accumulated other comprehensive income (loss) component is included in the computation of net periodic pension cost. Refer to Note 10 for additional details.

Revenue (Notes)

3 Months Ended

Mar. 29, 2019

Revenue from Contract with Customer [Abstract]

Revenue from Contract with Customer

REVENUE

The following tables present the Company’s revenues disaggregated by geographical region and revenue type for the three-month periods ended March 29, 2019 and March 30, 2018 ($ in millions). Sales taxes and other usage-based taxes collected from customers are excluded from revenue.



	Three-Month Period Ended March 29, 2019
	Life Sciences		Diagnostics		Dental		Environmental & Applied Solutions		Total
Geographical region:
North America	$	587.3	$	632.4	$	298.5	$	449.2	$	1,967.4
Western Europe	460.3		288.9		160.1		259.7		1,169.0
Other developed markets	149.3		92.0		40.4		28.9		310.6
High-growth markets	430.0		523.5		160.7		318.7		1,432.9
Total	$	1,626.9	$	1,536.8	$	659.7	$	1,056.5	$	4,879.9

Revenue type:
Recurring	$	1,068.2	$	1,324.1	$	487.8	$	582.2	$	3,462.3
Nonrecurring	558.7		212.7		171.9		474.3		1,417.6
Total	$	1,626.9	$	1,536.8	$	659.7	$	1,056.5	$	4,879.9



	Three-Month Period Ended March 30, 2018
	Life Sciences		Diagnostics		Dental		Environmental & Applied Solutions		Total
Geographical region:
North America	$	480.4	$	607.4	$	291.3	$	418.3	$	1,797.4
Western Europe	449.9		310.4		175.6		264.8		1,200.7
Other developed markets	144.9		92.2		43.9		31.6		312.6
High-growth markets	400.8		509.7		161.8		312.4		1,384.7
Total	$	1,476.0	$	1,519.7	$	672.6	$	1,027.1	$	4,695.4

Revenue type:
Recurring	$	970.4	$	1,308.5	$	488.0	$	557.0	$	3,323.9
Nonrecurring	505.6		211.2		184.6		470.1		1,371.5
Total	$	1,476.0	$	1,519.7	$	672.6	$	1,027.1	$	4,695.4

The Company sells equipment to customers as well as consumables, spare parts, software licenses and services, some of which customers purchase on a recurring basis. Consumables are typically critical to the use of the equipment and are typically used on a one-time or limited basis, requiring frequent replacement in the customer’s operating cycle. Examples of these consumables include reagents used in diagnostic tests, filters used in filtration, separation and purification processes and cartridges for marking and coding equipment. Additionally, some of the Company’s consumables are used on a standalone basis, such as dental implants and water treatment solutions. The Company separates its goods and services between those sold on a recurring basis and those sold on a nonrecurring basis. Recurring revenue includes revenue from consumables, services, spare parts, software licenses recognized over time, SaaS licenses, sales-and-usage based royalties and OTLs. Nonrecurring revenue includes sales from equipment, software licenses recognized at a point in time and STLs. OTLs and STLs are included in the above revenue amounts. For the three-month periods ended March 29, 2019 and March 30, 2018, revenue accounted for under Topic 842 and 840, Leases was $107 million and $97 million, respectively.

Remaining performance obligations related to Topic 606, Revenue from Contracts with Customers (“ASC 606”) represent the aggregate transaction price allocated to performance obligations with an original contract term greater than one year which are fully or partially unsatisfied at the end of the period. As of March 29, 2019, the aggregate amount of the transaction price allocated to remaining performance obligations was approximately $1.9 billion. The Company expects to recognize revenue on approximately 43% of the remaining performance obligations over the next 12 months, 27% recognized over the subsequent 12 months, and the remainder recognized thereafter.

The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets) and deferred revenue, customer deposits and billings in excess of revenue recognized (contract liabilities) on the Consolidated Condensed Balance Sheets. Most of the Company’s long-term contracts are billed as work progresses in accordance with the contract terms and conditions, either at periodic intervals or upon achievement of certain milestones. Often this results in billing occurring subsequent to revenue recognition resulting in contract assets. Contract assets are generally classified as other current assets in the Consolidated Condensed Balance Sheets. The balance of contract assets as of March 29, 2019 and December 31, 2018 were $97 million and $82 million, respectively.

The Company often receives cash payments from customers in advance of the Company’s performance resulting in contract liabilities. These contract liabilities are classified as either current or long-term in the Consolidated Condensed Balance Sheets based on the timing of when the Company expects to recognize revenue. As of March 29, 2019 and December 31, 2018, contract liabilities were $838 million and $799 million, respectively, and are included within accrued expenses and other liabilities and other long-term liabilities in the accompanying Consolidated Condensed Balance Sheets. Revenue recognized during the three-month periods ended March 29, 2019 and March 30, 2018 that was included in the contract liability balance on December 31, 2018 and at the date of adoption of ASC 606 on January 1, 2018 was $287 million and $265 million, respectively. Contract assets and liabilities are reported on the accompanying Consolidated Condensed Balance Sheets on a contract-by-contract basis.

Acquisitions

3 Months Ended

Mar. 29, 2019

Business Combinations [Abstract]

Acquisitions

ACQUISITIONS

For a description of the Company’s acquisition activity for the year ended December 31, 2018, reference is made to the financial statements as of and for the year ended December 31, 2018 and Note 3 thereto included in the Company’s 2018 Annual Report.

The Company continually evaluates potential acquisitions that either strategically fit with the Company’s existing portfolio or expand the Company’s portfolio into a new and attractive business area. The Company has completed a number of acquisitions that have been accounted for as purchases and have resulted in the recognition of goodwill in the Company’s financial statements. This goodwill arises because the purchase prices for these businesses reflect a number of factors including the future earnings and cash flow potential of these businesses, the multiple to earnings, cash flow and other factors at which similar businesses have been purchased by other acquirers, the competitive nature of the processes by which the Company acquired the businesses, avoidance of the time and costs which would be required (and the associated risks that would be encountered) to enhance the Company’s existing product offerings to key target markets and enter into new and profitable businesses and the complementary strategic fit and resulting synergies these businesses bring to existing operations.

The Company makes an initial allocation of the purchase price at the date of acquisition based upon its understanding of the fair value of the acquired assets and assumed liabilities. The Company obtains this information during due diligence and through other sources. In the months after closing, as the Company obtains additional information about these assets and liabilities, including through tangible and intangible asset appraisals, and learns more about the newly acquired business, it is able to refine the estimates of fair value and more accurately allocate the purchase price. Only items identified as of the acquisition date are considered for subsequent adjustment. The Company is continuing to evaluate certain pre-acquisition contingencies associated with its 2018 and 2019 acquisitions and is also in the process of obtaining valuations of certain plant and equipment, acquired intangible assets and certain acquisition-related liabilities in connection with its first quarter 2019 acquisition. The Company will make appropriate adjustments to the purchase price allocation prior to completion of the measurement period, as required.

During the three-month period ended March 29, 2019, the Company acquired one business for total consideration of $308 million in cash, net of cash acquired. The business acquired complements an existing unit of the Life Sciences segment. The aggregate annual sales of this business at the time of its acquisition, based on the company’s revenues for its last completed fiscal year prior to the acquisition, were $61 million. The Company preliminarily recorded an aggregate of $211 million of goodwill related to this acquisition.

The following summarizes the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition for the acquisition consummated during the three-month period ended March 29, 2019 ($ in millions):



Trade accounts receivable	$	7.7
Inventories	8.6
Property, plant and equipment	3.9
Goodwill	211.1
Other intangible assets, primarily customer relationships, trade names and technology	87.0
Trade accounts payable	(2.6		)
Other assets and liabilities, net	(7.5		)
Net cash consideration	$	308.2

Pro Forma Financial Information

The unaudited pro forma information for the periods set forth below gives effect to the 2019 and 2018 acquisitions as if they had occurred as of January 1, 2018. The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have been achieved had the acquisitions been consummated as of that time ($ in millions, except per share amounts):



	Three-Month Period Ended
	March 29, 2019		March 30, 2018
Sales	$	4,884.1	$	4,788.3
Net earnings attributable to common stockholders	326.1		552.4
Diluted net earnings per share	0.45		0.78

Pending Acquisition

On February 25, 2019, the Company entered into an Equity and Asset Purchase Agreement (the “GE Biopharma Purchase Agreement”) with General Electric Company (“GE”) to acquire the Biopharma Business of GE Life Sciences (the “GE Biopharma Business” or “GE Biopharma”) for a cash purchase price of approximately $21.0 billion, subject to certain adjustments, and the assumption of approximately $0.4 billion of pension liabilities (the “GE Biopharma Acquisition”). The GE Biopharma Business is a leading provider of instruments, consumables and software that support the research, discovery, process development and manufacturing workflows of biopharmaceutical drugs. Based on unaudited preliminary financial measures provided by GE, the GE Biopharma Business generated revenues of approximately $3.0 billion in 2018. The GE Biopharma Acquisition is expected to provide additional sales and earnings growth opportunities for the Company’s Life Sciences segment by expanding the business’ geographic and product line diversity, including new product and service offerings that complement the Company’s current biologics workflow solutions. The Company expects to include the GE Biopharma Business within the Life Sciences segment. The transaction is expected to be completed in the fourth quarter of 2019, subject to customary conditions, including receipt of applicable regulatory approvals.

The Company expects to finance the GE Biopharma Acquisition with approximately $3.0 billion of proceeds from the March 1, 2019 underwritten public offerings of its Common Stock and Mandatory Convertible Preferred Stock (“MCPS”), proceeds from the issuance of debt or other borrowings and available cash on hand. Refer to Note 14 for additional information related to the March 1, 2019 public offerings.

Dental Initial Public Offering	3 Months Ended
Dental Initial Public Offering	Mar. 29, 2019
Discontinued Operations and Disposal Groups [Abstract]
Dental Initial Public Offering	DENTAL INITIAL PUBLIC OFFERING In July 2018, the Company announced its intention to spin-off its Dental business into a separate publicly-traded company (the “Dental Separation”). On February 25, 2019, in connection with the announcement of the GE Biopharma Acquisition, the Company also announced a modification of its plans with respect to the Dental business, specifically that it now intends to conduct an initial public offering of shares of the Dental business (the “Dental IPO”) in the second half of 2019, subject to the satisfaction of certain conditions, including obtaining final approval from the Danaher Board of Directors, favorable rulings from the Internal Revenue Service (“IRS”) and other regulatory approvals. All assets, liabilities, revenues and expenses of the Dental business are included in continuing operations of the Company in these Consolidated Condensed Financial Statements. Subsequent to the anticipated Dental IPO, the Company currently intends to distribute to our shareholders all or a portion of our remaining equity interest in the Dental business, which may include the spin-off of Dental business shares effected as a dividend to all our shareholders, the split-off of Dental business shares in exchange for Danaher shares or other securities, or any combination thereof in one transaction or in a series of transactions (collectively, “the Distribution”). While the Company currently intends to effect the Distribution, the Company has no obligation to pursue or consummate any further dispositions of our ownership in the Dental business, including through the Distribution, by any specified date or at all. If pursued, the Distribution may be subject to various conditions, including receipt of any necessary regulatory or other approvals, the existence of satisfactory market conditions, and the receipt of an opinion of counsel to the effect that the separation of the Dental business in connection with the IPO, together with such Distribution, will be tax-free to the Company and the Company’s shareholders for U.S. federal income tax purposes. The conditions to the Distribution may not be satisfied; the Company may decide not to consummate the Distribution even if the conditions are satisfied; or we may decide to waive one or more of these conditions and consummate the Distribution even if all of the conditions are not satisfied. In addition to or in lieu of the Distribution, subsequent to the Dental IPO the Company may sell additional shares of the Dental business in one or more publicly registered offerings or private placements. The Company cannot assure whether or when any such transaction will be consummated or as to the final terms of any such transaction.

Leases (Notes)

3 Months Ended

Mar. 29, 2019

Leases [Abstract]

Leases

LEASES

The Company has operating leases for office space, warehouses, distribution centers, research and development facilities, manufacturing locations and certain equipment, primarily automobiles. Many leases include one or more options to renew, some of which include options to extend the leases for up to 30 years, and some leases include options to terminate the leases within 30 days. In certain of the Company’s lease agreements, the rental payments are adjusted periodically to reflect actual charges incurred for capital area maintenance, utilities, inflation and/or changes in other indexes. The Company’s finance leases were not material as of March 29, 2019 and for the three-month period then ended. ROU assets arising from finance leases are included in property, plant and equipment, net and the liabilities are included in notes payable and current portion of long-term debt and long-term debt in the accompanying Consolidated Condensed Balance Sheets.

For the three-month period ended March 29, 2019, the components of operating lease expense were as follows ($ in millions):



Fixed operating lease expense ^(a)	$	63.4
Variable operating lease expense	12.0
Total operating lease expense	$	75.4

^(a)Includes short-term leases and sublease income, both of which were immaterial.

Supplemental cash flow information related to the Company’s operating leases for the three-month period ended March 29, 2019 was as follows ($ in millions):



Cash paid for amounts included in the measurement of operating lease liabilities	$	61.9
ROU assets obtained in exchange for operating lease obligations	39.6

The following table presents the lease balances within the Consolidated Condensed Balance Sheet, weighted average remaining lease term, and weighted average discount rates related to the Company’s operating leases as of March 29, 2019 ($ in millions except for the weighted average remaining lease term and weighted average discount rate):



Lease Assets and Liabilities	Classification
Assets:
Operating lease ROU assets	Other long-term assets	$	946.7

Liabilities:
Current:
Operating lease liabilities	Accrued expenses and other liabilities	$	186.1
Long-term:
Operating lease liabilities	Other long-term liabilities	800.0
Total operating lease liabilities		$	986.1

Weighted average remaining lease term		7 years
Weighted average discount rate		3.3		%

The following table presents the maturity of the Company’s operating lease liabilities as of March 29, 2019 ($ in millions):



Remainder of 2019	$	163.3
2020	183.5
2021	149.0
2022	125.8
2023	109.7
Thereafter	395.3
Total operating lease payments	1,126.6
Less: imputed interest	140.5
Total operating lease liabilities	$	986.1

As of March 29, 2019, the Company had no additional significant operating or finance leases that had not yet commenced.

Goodwill

3 Months Ended

Mar. 29, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill

GOODWILL

The following is a rollforward of the Company’s goodwill ($ in millions):



Balance, December 31, 2018	$	25,906.0
Attributable to 2019 acquisitions	211.1
Adjustments due to finalization of purchase price allocations	(6.1		)
Foreign currency translation and other	(109.6		)
Balance, March 29, 2019	$	26,001.4

The carrying value of goodwill by segment is summarized as follows ($ in millions):



	March 29, 2019		December 31, 2018
Life Sciences	$	13,463.0	$	13,311.0
Diagnostics	6,902.9		6,925.6
Dental	3,301.0		3,325.5
Environmental & Applied Solutions	2,334.5		2,343.9
Total	$	26,001.4	$	25,906.0

The Company has not identified any “triggering” events which indicate an impairment of goodwill in the three-month period ended March 29, 2019.

Fair Value Measurements

3 Months Ended

Mar. 29, 2019

Fair Value Disclosures [Abstract]

Fair Value Measurements

FAIR VALUE MEASUREMENTS

Accounting standards define fair value based on an exit price model, establish a framework for measuring fair value where the Company’s assets and liabilities are required to be carried at fair value and provide for certain disclosures related to the valuation methods used within a valuation hierarchy as established within the accounting standards. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in markets that are not active, or other observable characteristics for the asset or liability, including interest rates, yield curves and credit risks, or inputs that are derived principally from, or corroborated by, observable market data through correlation. Level 3 inputs are unobservable inputs based on the Company’s assumptions. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement in its entirety.

A summary of financial assets and liabilities that are measured at fair value on a recurring basis were as follows ($ in millions):



	Quoted Prices in Active Market (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
March 29, 2019:
Assets:
Available-for-sale debt securities	$	—	$	36.8	$	—	$	36.8
Investment in equity securities	—		—		193.1		193.1
Cross-currency swap derivative contracts	—		17.1		—		17.1
Liabilities:
Cross-currency swap derivative contracts	—		2.3		—		2.3
Deferred compensation plans	—		66.3		—		66.3

December 31, 2018:
Assets:
Available-for-sale debt securities	$	—	$	38.3	$	—	$	38.3
Investment in equity securities	—		—		148.9		148.9
Liabilities:
Deferred compensation plans	—		60.9		—		60.9

Available-for-sale debt securities, which are included in other long-term assets in the accompanying Consolidated Condensed Balance Sheets, are measured at fair value using quoted prices reported by investment brokers and dealers based on the underlying terms of the security and comparison to similar securities traded on an active market. As of March 29, 2019, available-for-sale debt securities primarily include U.S. Treasury Notes and corporate debt securities, which are valued based on instruments with similar terms traded on an active market.

The Company’s investments in equity securities are classified as Level 3 in the fair value hierarchy because the Company estimates the fair value based on the measurement alternative and adjusts for impairments and observable price changes with a same or similar security from the same issuer within net earnings (the “Fair Value Alternative”). The investments in equity securities includes investments that the Company has made as a limited partner in a partnership for which the underlying investments are recorded on a fair value basis.

The cross-currency swap derivative contracts are used to partially hedge the Company’s net investments in foreign operations against adverse movements in exchange rates between the U.S. dollar and the Danish kroner, Japanese yen, euro and the Swiss franc. The cross-currency swap derivative contracts are classified as Level 2 in the fair value hierarchy as they are measured using the income approach with the relevant interest rates and foreign currency current exchange rates and forward curves as inputs. Refer to Note 9 for additional information.

The Company has established nonqualified deferred compensation programs that permit the Company to make tax-deferred contributions to officers and certain other employees, and also permit directors, officers and certain other employees to voluntarily defer taxation on a portion of their compensation. All amounts deferred under such plans are unfunded, unsecured obligations of the Company and are presented as a component of the Company’s compensation and benefits accrual included in other long-term liabilities in the accompanying Consolidated Condensed Balance Sheets. Non-director participants may choose among alternative earning rates for the amounts they defer, which are primarily based on investment options within the Company’s 401(k) program. Changes in the deferred compensation liability under these programs are recognized based on changes in the fair value of the participants’ accounts, which are based on the applicable earnings rates. Amounts voluntarily deferred by directors and amounts unilaterally contributed to participant accounts by the Company are deemed invested in the Company’s common stock and future distributions of such contributions (as well as future distributions of any voluntary deferrals allocated at any time to the Danaher common stock investment option) will be made solely in shares of common stock. As a result, Company contributions to these programs and voluntary deferrals allocated at any time to the Danaher common stock investment option are not reflected in the above amounts.

Fair Value of Financial Instruments

The carrying amounts and fair values of the Company’s financial instruments were as follows ($ in millions):



	March 29, 2019				December 31, 2018
	Carrying Amount		Fair Value		Carrying Amount		Fair Value
Assets:
Available-for-sale debt securities	$	36.8	$	36.8	$	38.3	$	38.3
Investment in equity securities	193.1		193.1		148.9		148.9
Cross-currency swap derivative contracts	17.1		17.1		—		—
Liabilities:
Cross-currency swap derivative contracts	2.3		2.3		—		—
Notes payable and current portion of long-term debt	36.6		36.6		51.8		51.8
Long-term debt	9,458.2		9,848.5		9,688.5		9,990.6

As of March 29, 2019 and December 31, 2018, investments in non-marketable equity securities were categorized as Level 3, available-for-sale debt securities and cross-currency swap derivative contracts were categorized as Level 2 and short and long-term borrowings were categorized as Level 1.

The fair value of long-term borrowings was based on quoted market prices. The difference between the fair value and the carrying amounts of long-term borrowings (other than the Company’s Liquid Yield Option Notes due 2021 (the “LYONs”)) is attributable to changes in market interest rates and/or the Company’s credit ratings subsequent to the incurrence of the borrowing. In the case of the LYONs, differences in the fair value from the carrying value are attributable to changes in the price of the Company’s common stock due to the LYONs’ conversion features. The fair values of borrowings with original maturities of one year or less, as well as cash and cash equivalents, trade accounts receivable, net and trade accounts payable approximate their carrying amounts due to the short-term maturities of these instruments.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Financing

3 Months Ended

Mar. 29, 2019

Debt Disclosure [Abstract]

Financing

FINANCING

As of March 29, 2019, the Company was in compliance with all of its debt covenants. The components of the Company’s debt were as follows ($ in millions):



	March 29, 2019		December 31, 2018
U.S. dollar-denominated commercial paper	$	—	$	72.8
Euro-denominated commercial paper (€2.1 billion and €2.1 billion, respectively)	2,327.0		2,377.5
1.0% senior unsecured notes due 2019 (€600.0 million aggregate principal amount) (the “2019 Euronotes”)	672.7		687.0
2.4% senior unsecured notes due 2020	498.7		498.5
5.0% senior unsecured notes due 2020 (the “2020 Assumed Pall Notes”)	386.6		386.7
Zero-coupon LYONs due 2021	44.3		56.2
0.352% senior unsecured notes due 2021 (¥30.0 billion aggregate principal amount) (the “2021 Yen Notes”)	270.2		273.2
1.7% senior unsecured notes due 2022 (€800.0 million aggregate principal amount) (the “2022 Euronotes”)	894.1		913.2
Floating rate senior unsecured notes due 2022 (€250.0 million aggregate principal amount) (the “Floating Rate 2022 Euronotes”)	279.7		285.7
0.5% senior unsecured bonds due 2023 (CHF 540.0 million aggregate principal amount) (the “2023 CHF Bonds”)	543.4		550.7
2.5% senior unsecured notes due 2025 (€800.0 million aggregate principal amount) (the “2025 Euronotes”)	893.4		912.6
3.35% senior unsecured notes due 2025	496.9		496.8
0.3% senior unsecured notes due 2027 (¥30.8 billion aggregate principal amount) (the “2027 Yen Notes”)	276.9		279.9
1.2% senior unsecured notes due 2027 (€600.0 million aggregate principal amount) (the “2027 Euronotes”)	667.6		682.0
1.125% senior unsecured bonds due 2028 (CHF 210.0 million aggregate principal amount) (the “2028 CHF Bonds”)	215.2		218.1
0.65% senior unsecured notes due 2032 (¥53.2 billion aggregate principal amount) (the “2032 Yen Notes”)	478.1		483.4
4.375% senior unsecured notes due 2045	499.4		499.3
Other	50.6		66.7
Total debt	9,494.8		9,740.3
Less: currently payable	36.6		51.8
Long-term debt	$	9,458.2	$	9,688.5

For additional details regarding the Company’s debt financing, refer to Note 10 of the Company’s financial statements as of and for the year ended December 31, 2018 included in the Company’s 2018 Annual Report.

The Company satisfies any short-term liquidity needs that are not met through operating cash flow and available cash primarily through issuances of commercial paper under its U.S. dollar and euro-denominated commercial paper programs. Credit support for the commercial paper programs is generally provided by the Company’s $4.0 billion unsecured, multi-year revolving credit facility with a syndicate of banks that expires on July 10, 2020 (the “Credit Facility”), which can also be used for working capital and other general corporate purposes described below. As of March 29, 2019, no borrowings were outstanding under the Credit Facility and the Company was in compliance with all covenants thereunder. In addition to the Credit Facility, the Company has also entered into reimbursement agreements with various commercial banks to support the issuance of letters of credit.

As of March 29, 2019, borrowings outstanding under the Company’s euro-denominated commercial paper program had a weighted average annual interest rate of negative 0.3% and a weighted average remaining maturity of approximately 37 days. There were no borrowings outstanding under the Company’s U.S. dollar-denominated commercial paper program as of March 29, 2019.

The Company has classified the $673 million of 2019 Euronotes and approximately $2.3 billion of its borrowings outstanding under the euro-denominated commercial paper program as of March 29, 2019 as long-term debt in the accompanying Consolidated Condensed Balance Sheet as the Company had the intent and ability, as supported by availability under the Credit Facility, to refinance these borrowings for at least one year from the balance sheet date.

Debt discounts, premiums and debt issuance costs totaled $17 million and $19 million as of March 29, 2019 and December 31, 2018, respectively, and have been netted against the aggregate principal amounts of the related debt in the components of debt table above.

Guarantors of Debt

The Company has guaranteed long-term debt and commercial paper issued by certain of its wholly-owned subsidiaries. The 2019 Euronotes, 2022 Euronotes, Floating Rate 2022 Euronotes, 2025 Euronotes and 2027 Euronotes were issued by DH Europe Finance S.A. (“Danaher International”). The 2023 CHF Bonds and 2028 CHF Bonds were issued by DH Switzerland Finance S.A. (“Danaher Switzerland”). The 2021 Yen Notes, 2027 Yen Notes and 2032 Yen Notes were issued by DH Japan Finance S.A. (“Danaher Japan”). Each of Danaher International, Danaher Switzerland and Danaher Japan are wholly-owned finance subsidiaries of Danaher Corporation. All of the securities issued by each of these entities, as well as the 2020 Assumed Pall Notes, are fully and unconditionally guaranteed by the Company and these guarantees rank on parity with the Company’s unsecured and unsubordinated indebtedness.

LYONs Redemption

During the three-month period ended March 29, 2019, holders of certain of the Company’s LYONs converted such LYONs into an aggregate of approximately 486 thousand shares of the Company’s common stock, par value $0.01 per share. The Company’s deferred tax liability associated with the book and tax basis difference in the converted LYONs of $5 million was transferred to additional paid-in capital as a result of the conversions.

Hedging Transactions And Derivative Financial Instruments (Notes)

3 Months Ended

Mar. 29, 2019

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Hedging Transactions and Derivative Financial Instruments

HEDGING TRANSACTIONS AND DERIVATIVE FINANCIAL INSTRUMENTS

The Company uses cross-currency swap derivative contracts to partially hedge its net investments in foreign operations against adverse movements in exchange rates between the U.S. dollar and the Danish kroner, Japanese yen, euro and the Swiss franc. The cross-currency swap derivative contracts are agreements to exchange fixed-rate payments in one currency for fixed-rate payments in another currency. In January 2019, the Company entered into cross-currency swap derivative contracts on approximately $1.9 billion which corresponds with certain of its U.S. dollar-denominated bonds. These contracts effectively convert the Company’s U.S. dollar-denominated bonds to obligations denominated in Danish kroner, Japanese yen, euro and Swiss franc, and will partially offset the impact of changes in currency rates on foreign currency denominated net investments in future periods. The changes in the fair value of these instruments are recorded in accumulated other comprehensive income (loss) in stockholders’ equity, partially offsetting the foreign currency translation adjustment of the Company’s related net investment that is also recorded in accumulated other comprehensive income (loss) in the Company’s Consolidated Condensed Statements of Stockholders’ Equity. Any ineffective portions of net investment hedges are reclassified from accumulated other comprehensive income (loss) into earnings during the period of change. The interest income or expense from these swaps are recorded in interest expense in the Company’s Consolidated Condensed Statements of Earnings consistent with the interest expense attributable to the underlying debt. These instruments will mature on dates ranging from June 2019 to September 2028.

The Company incurred foreign currency denominated long-term debt as partial hedges of its net investments in foreign operations against adverse movements in exchange rates between the U.S. dollar and the euro, Japanese yen, Swiss franc, British pound and Canadian dollar. These foreign currency denominated long-term debt issuances are designated and qualify as nonderivative hedging instruments. Accordingly, the foreign currency translation of these debt instruments is recorded in accumulated other comprehensive income (loss) in stockholders’ equity in the accompanying Consolidated Condensed Balance Sheets, offsetting the foreign currency translation adjustment of the Company’s related net investment that is also recorded in accumulated other comprehensive income (loss). Any ineffective portions of net investment hedges are reclassified from accumulated other comprehensive income (loss) into earnings during the period of change. These instruments will mature on dates ranging from June 2019 to May 2032.

The following table summarizes the notional values and pretax impact of changes in the fair values of instruments designated as net investment hedges ($ in millions):



	Three-Month Period Ended March 29, 2019
	Notional Amount		Gain (Loss) Recognized in OCI
Foreign currency contracts	$	1,875.0	$	14.8
Foreign currency denominated debt	7,518.3		137.8
Total	$	9,393.3	$	152.6

The Company did not reclassify any deferred gains or losses related to net investment hedges from accumulated other comprehensive income (loss) to earnings during the three-month period ended March 29, 2019. In addition, the Company did not have any ineffectiveness related to net investment hedges during the three-month period ended March 29, 2019. The cash inflows and outflows associated with the Company’s derivative contracts designated as net investment hedges are classified in the line item “all other investing activities” in the accompanying Consolidated Condensed Statement of Cash Flows.

The Company’s derivative instruments, as well as its nonderivative debt instruments designated and qualifying as net investment hedges, were classified as of March 29, 2019 in the Company’s Consolidated Condensed Balance Sheet as follows ($ in millions):



	March 29, 2019
Derivative assets:
Prepaid expenses and other current assets	$	17.1

Derivative liabilities:
Accrued expenses and other liabilities	2.3

Nonderivative hedging instruments:
Long-term debt	7,518.3

Amounts related to the Company’s derivatives expected to be reclassified from accumulated other comprehensive income (loss) to net earnings during the next 12 months are not significant.

Defined Benefit Plans

3 Months Ended

Mar. 29, 2019

Retirement Benefits [Abstract]

Defined Benefit Plans

DEFINED BENEFIT PLANS

The following sets forth the components of the Company’s net periodic benefit cost of the noncontributory defined benefit pension plans ($ in millions):



	Three-Month Period Ended
	March 29, 2019			March 30, 2018
U.S. pension benefits:
Service cost	$	(1.6	)	$	(2.1	)
Interest cost	(22.3		)	(20.2		)
Expected return on plan assets	31.6			33.1
Amortization of actuarial loss	(6.3		)	(7.8		)
Amortization of prior service cost	(0.2		)	(0.3		)
Net periodic pension benefit	$	1.2		$	2.7

Non-U.S. pension benefits:
Service cost	$	(8.1	)	$	(8.7	)
Interest cost	(6.7		)	(6.7		)
Expected return on plan assets	10.9			12.1
Amortization of actuarial gain (loss)	0.1			(1.5		)
Amortization of prior service (cost) credit	(1.2		)	0.1
Settlement loss recognized	—			(0.4		)
Net periodic pension cost	$	(5.0	)	$	(5.1	)

The following sets forth the components of the Company’s net periodic benefit cost of the other postretirement employee benefit plans ($ in millions):



	Three-Month Period Ended
	March 29, 2019			March 30, 2018
Service cost	$	(0.1	)	$	(0.1	)
Interest cost	(1.2		)	(1.2		)
Amortization of prior service credit	0.5			0.6
Net periodic cost	$	(0.8	)	$	(0.7	)

The net periodic benefit cost of the noncontributory defined benefit pension plans and other postretirement employee benefit plans incurred during the three-month periods ended March 29, 2019 and March 30, 2018 are reflected in the following captions in the accompanying Consolidated Condensed Statements of Earnings ($ in millions):



	Three-Month Period Ended
	March 29, 2019			March 30, 2018
Service cost:
Cost of sales	$	(2.0	)	$	(2.1	)
Selling, general and administrative expenses	(7.8		)	(8.8		)
Total service cost	(9.8		)	(10.9		)
Other net periodic benefit costs:
Other income, net	5.2			7.8
Total	$	(4.6	)	$	(3.1	)

Employer Contributions

During 2019, the Company’s cash contribution requirements for its U.S. and non-U.S. defined benefit pension plans are forecasted to be approximately $10 million and $50 million, respectively. The ultimate amounts to be contributed depend upon, among other things, legal requirements, underlying asset returns, the plan’s funded status, the anticipated tax deductibility of the contribution, local practices, market conditions, interest rates and other factors.

Income Taxes

3 Months Ended

Mar. 29, 2019

Income Tax Disclosure [Abstract]

Income Taxes

INCOME TAXES

The following table summarizes the Company’s effective tax rate:



	Three-Month Period Ended
	March 29, 2019		March 30, 2018
Effective tax rate	53.7	%	20.5	%

The effective tax rate for 2019 differs from the U.S. federal statutory rate of 21.0% principally due to the impact of net discrete tax charges of $242 million ($0.34 per diluted share) related primarily to changes in estimates associated with prior period uncertain tax positions and audit settlements, net of the release of valuation allowances associated with certain foreign tax credits, tax benefits resulting from a change in tax law, and excess tax benefits from stock-based compensation. These discrete tax charges increased the reported tax rate by 34.0%. These provisions were partially offset by benefits from the impact of earnings outside the United States which generally are taxed at rates lower than the U.S. federal rate.

The Company’s effective tax rate for 2018 was slightly lower than the U.S. federal statutory rate of 21.0% due principally to the impact of the Company’s earnings outside the United States which generally are taxed at rates lower than the U.S. federal rate. The 2018 effective tax rate includes the benefit of a lower U.S. corporate income tax rate of 21.0% from the enactment of the Tax Cuts and Jobs Act (“TCJA”), partially offset by a new minimum tax on certain non-U.S. earnings. The effective tax rate for the three-month period ended March 30, 2018 also includes tax benefits for release of reserves upon the expiration of statutes of limitation and excess tax benefits from stock-based compensation which were offset by changes in estimates associated with prior period uncertain tax provisions and other matters.

In the fourth quarter of 2018 and first quarter of 2019, the IRS has proposed significant adjustments to the Company’s taxable income for the years 2012 through 2015 with respect to the deferral of tax on certain premium income related to the Company’s self-insurance programs. The proposed adjustments would increase the Company’s taxable income over the 2012-2015 period by approximately $2.7 billion. Management believes the positions the Company has taken in its U.S. tax returns are in accordance with the relevant tax laws, intends to vigorously defend these positions and is currently considering all of its alternatives. Due to the enactment of the TCJA in 2017 and the resulting reduction in the U.S. corporate tax rate for years after 2017, the Company revalued its deferred tax liabilities related to the temporary differences associated with this deferred premium income from 35.0% to 21.0%. If the Company is not successful in defending these assessments, the taxes owed to the IRS may be computed under the previous 35.0% statutory tax rate and the Company may be required to revalue the related deferred tax liabilities from 21.0% to 35.0%, which in addition to any interest due on the amounts assessed, would require a charge to future earnings. The ultimate resolution of this matter is uncertain, could take many years and could result in a material adverse impact to the Company’s Consolidated Condensed Financial Statements, including its cash flows and effective tax rate.

Tax authorities in Denmark have raised significant issues related to interest accrued by certain of the Company’s subsidiaries. On December 10, 2013, the Company received assessments from the Danish tax authority (“SKAT”) totaling approximately DKK 1.7 billion including interest through March 29, 2019 (approximately $253 million based on the exchange rate as of March 29, 2019), imposing withholding tax relating to interest accrued in Denmark on borrowings from certain of the Company’s subsidiaries for the years 2004-2009. The Company appealed these assessments to the National Tax Tribunal in 2014, which appeal has been pending awaiting the outcome of other cases brought to the Court of Justice of the European Union (“CJEU”). The Company is currently in discussions with SKAT and anticipates receiving an assessment for similar withholding tax matters for the years 2010-2012 totaling approximately DKK 994 million including interest through March 29, 2019 (approximately $149 million based on the exchange rate as of March 29, 2019). In February 2019, the CJEU decided several other cases related to Danish withholding tax on dividends and interest. In these cases, the CJEU ruled that the exemption of interest payments from withholding taxes provided in the applicable European Union (“EU”) directive should be denied where taxpayers use the directive for abusive or fraudulent purposes, and that it is up to the national courts to make this determination. Management believes the positions the Company has taken in Denmark are in accordance with the relevant tax laws and is vigorously defending its positions. The Company intends on pursuing this matter through the Danish High Court should the appeal to the Tax Tribunal be unsuccessful. The Company will continue to monitor decisions of both the Danish courts and the CJEU and evaluate the impact of these court rulings on the Company’s tax positions in Denmark. The ultimate resolution of this matter is uncertain, could take many years, and could result in a material adverse impact to the Company’s Consolidated Condensed Financial Statements, including its effective tax rate.

Nonoperating Income (Expense)	3 Months Ended
Nonoperating Income (Expense)	Mar. 29, 2019
Other Income and Expenses [Abstract]
Nonoperating Income (Expense)	NONOPERATING INCOME (EXPENSE) The Company disaggregates the service cost component of net periodic benefit costs of the noncontributory defined benefit pension plans and other postretirement employee benefit plans and presents the other components of net periodic benefit cost in other income, net. These other components include the assumed rate of return on plan assets partially offset by amortization of actuarial losses and interest and aggregated to a gain of $5 million and $8 million for the three-month periods ended March 29, 2019 and March 30, 2018, respectively.

Commitments And Contingencies

3 Months Ended

Mar. 29, 2019

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

COMMITMENTS AND CONTINGENCIES

For a description of the Company’s litigation and contingencies, refer to Note 17 of the Company’s financial statements as of and for the year ended December 31, 2018 included in the Company’s 2018 Annual Report. The Company reviews the adequacy of its legal reserves on a quarterly basis and establishes reserves for loss contingencies that are both probable and reasonably estimable. During the three-month period ended March 29, 2019, the Company recorded a provision of an additional $36 million ($29 million after-tax or $0.04 per diluted share) for costs and estimated damages related to a legal contingency.

The Company generally accrues estimated warranty costs at the time of sale. In general, manufactured products are warranted against defects in material and workmanship when properly used for their intended purpose, installed correctly and appropriately maintained. Warranty periods depend on the nature of the product and range from the date of such sale up to the life of the product. The amount of the accrued warranty liability is determined based on historical information such as past experience, product failure rates or number of units repaired, estimated cost of material and labor and in certain instances estimated property damage. The accrued warranty liability is reviewed on a quarterly basis and may be adjusted as additional information regarding expected warranty costs becomes known.

The following is a rollforward of the Company’s accrued warranty liability ($ in millions):



Balance, December 31, 2018	$	77.4
Accruals for warranties issued during the period	18.0
Settlements made	(17.2		)
Effect of foreign currency translation	(0.2		)
Balance, March 29, 2019	$	78.0

Stock Transactions And Stock-Based Compensation

3 Months Ended

Mar. 29, 2019

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock Transactions And Stock-Based Compensation

STOCK TRANSACTIONS AND STOCK-BASED COMPENSATION

Neither the Company nor any “affiliated purchaser” repurchased any shares of Company common stock during the three-month period ended March 29, 2019. On July 16, 2013, the Company’s Board of Directors approved a repurchase program (the “Repurchase Program”) authorizing the repurchase of up to 20 million shares of the Company’s common stock from time to time on the open market or in privately negotiated transactions. As of March 29, 2019, 20 million shares remained available for repurchase pursuant to the Repurchase Program.

On March 1, 2019, the Company completed the underwritten public offering of 12.1 million shares of Danaher common stock at a price to the public of $123.00 per share (the “Common Stock Offering”), resulting in net proceeds of approximately $1.4 billion, after deducting expenses and the underwriters’ discount of $45 million. Simultaneously, the Company completed the underwritten public offering of 1.65 million shares of its 4.75% Mandatory Convertible Preferred Stock, Series A (“MCPS”), without par value and with a liquidation preference of $1,000 per share (the “MCPS Offering”), resulting in net proceeds of approximately $1.6 billion, after deducting expenses and the underwriters’ discount of $50 million. The Company intends to use the net proceeds from the Common Stock Offering and the MCPS Offering to fund a portion of the cash consideration payable for, and certain costs associated with, the GE Biopharma Acquisition. Pending completion of the GE Biopharma Acquisition, the Company intends to invest the net proceeds in short-term bank deposits and/or interest-bearing, investment-grade securities.

Unless converted or redeemed earlier in accordance with the terms of the applicable certificate of designations, each share of MCPS will mandatorily convert on the mandatory conversion date, which is expected to be April 15, 2022, into between 6.6368 and 8.1300 shares of the Company’s common stock, subject to customary anti-dilution adjustments. The number of shares of the Company’s common stock issuable upon conversion will be determined based on the average volume-weighted average price per share of the Company’s common stock over the 20 consecutive trading day period beginning on, and including, the 21st scheduled trading day immediately before April 15, 2022. Subject to certain exceptions, at any time prior to April 15, 2022, holders may elect to convert each share of the MCPS into 6.6368 shares of common stock, subject to customary anti-dilution adjustments. In the event of a fundamental change, the MCPS will convert at the fundamental change rates specified in the certificate of designations, and the holders of MCPS would be entitled to a fundamental change make-whole dividend.

Holders of MCPS will be entitled to receive, when and if declared by the Company’s Board of Directors, cumulative dividends at the annual rate of 4.75% of the liquidation preference of $1,000 per share (equivalent to $47.50 annually per share), payable in cash or, subject to certain limitations, by delivery of shares of the Company’s common stock or any combination of cash and shares of the Company’s common stock, at the Company’s election. If declared, dividends on the MCPS will be payable quarterly on January 15, April 15, July 15 and October 15 of each year (commencing on July 15, 2019 to, and including, April 15, 2022), to the holders of record of the MCPS as they appear on the Company’s stock register at the close of business on the immediately preceding December 31, March 31, June 30 and September 30, respectively.

If the GE Biopharma Acquisition has not closed on or before 5:00 p.m. (New York City time) on August 25, 2020, the GE Biopharma Purchase Agreement is terminated or the Company’s Board of Directors, in its good faith judgment, determines that the GE Biopharma Acquisition will not occur, the Company has the option to redeem the shares of MCPS, in whole but not in part, subject to certain terms and conditions.

For a full description of the Company’s stock-based compensation programs, refer to Note 18 of the Company’s financial statements as of and for the year ended December 31, 2018 included in the Company’s 2018 Annual Report. As of March 29, 2019, approximately 48 million shares of the Company’s common stock were reserved for issuance under the 2007 Omnibus Incentive Plan.

The following summarizes the components of the Company’s stock-based compensation expense ($ in millions):



	Three-Month Period Ended
	March 29, 2019			March 30, 2018
Restricted stock units (“RSUs”)/performance stock units (“PSUs”):
Pretax compensation expense	$	24.3		$	20.9
Income tax benefit	(5.1		)	(4.4		)
RSU/PSU expense, net of income taxes	19.2			16.5
Stock options:
Pretax compensation expense	14.9			12.4
Income tax benefit	(3.2		)	(2.6		)
Stock option expense, net of income taxes	11.7			9.8
Total stock-based compensation:
Pretax compensation expense	39.2			33.3
Income tax benefit	(8.3		)	(7.0		)
Total stock-based compensation expense, net of income taxes	$	30.9		$	26.3

Stock-based compensation has been recognized as a component of selling, general and administrative expenses in the accompanying Consolidated Condensed Statements of Earnings. As of March 29, 2019, $246 million of total unrecognized compensation cost related to RSUs/PSUs is expected to be recognized over a weighted average period of approximately three years. As of March 29, 2019, $209 million of total unrecognized compensation cost related to stock options is expected to be recognized over a weighted average period of approximately three years. Future compensation amounts will be adjusted for any changes in estimated forfeitures.

Net Earnings Per Share

3 Months Ended

Mar. 29, 2019

Earnings Per Share [Abstract]

Net Earnings Per Share

NET EARNINGS PER SHARE

Basic net earnings per share (“EPS”) is calculated by dividing net earnings attributable to common stockholders by the weighted average number of common shares outstanding for the applicable period. Diluted net EPS is computed based on the weighted average number of common shares outstanding increased by the number of additional shares that would have been outstanding had the potentially dilutive common shares been issued and reduced by the number of shares the Company could have repurchased with the proceeds from the issuance of the potentially dilutive shares. For the three-month period ended March 29, 2019, no options to purchase shares were excluded from the diluted EPS calculation. For the three-month period ended March 30, 2018, approximately three million options to purchase shares were not included in the diluted EPS calculation as the impact of their inclusion would have been anti-dilutive.

The impact of the MCPS calculated under the if-converted method was anti-dilutive, and as such 12.9 million shares underlying the MCPS were excluded from the dilutive EPS calculation for the three-month period ended March 29, 2019.

Information related to the calculation of net earnings per share is summarized as follows ($ and shares in millions, except per share amounts):



	Three-Month Period Ended
	March 29, 2019			March 30, 2018
Numerator:
Net earnings	$	333.8		$	566.6
Adjustment for interest on convertible debentures	0.5			0.6
MCPS dividends	(6.5		)	—
Net earnings attributable to common stockholders after assumed conversions for diluted EPS	$	327.8		$	567.2

Denominator:
Weighted average common shares outstanding used in basic EPS	707.6			698.6
Incremental common shares from:
Assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs	8.7			8.3
Assumed conversion of the convertible debentures	2.2			2.6
Weighted average common shares outstanding used in diluted EPS	718.5			709.5

Basic EPS	$	0.46		$	0.81
Diluted EPS	$	0.46		$	0.80

Segment Information

3 Months Ended

Mar. 29, 2019

Segment Reporting [Abstract]

Segment Information

SEGMENT INFORMATION

The Company operates and reports its results in four separate business segments consisting of the Life Sciences, Diagnostics, Dental and Environmental & Applied Solutions segments. When determining the reportable segments, the Company

aggregated operating segments based on their similar economic and operating characteristics. Operating profit represents total revenues less operating expenses, excluding nonoperating income and expense, interest and income taxes. Operating profit amounts in the Other segment consist of unallocated corporate costs and other costs not considered part of management’s evaluation of reportable segment operating performance. Intersegment amounts are not significant and are eliminated to arrive at consolidated totals.

Segment results are shown below ($ in millions):



	Three-Month Period Ended
	March 29, 2019			March 30, 2018
Sales:
Life Sciences	$	1,626.9		$	1,476.0
Diagnostics	1,536.8			1,519.7
Dental	659.7			672.6
Environmental & Applied Solutions	1,056.5			1,027.1
Total	$	4,879.9		$	4,695.4

Operating profit:
Life Sciences	$	309.0		$	271.3
Diagnostics	233.1			248.0
Dental	48.2			50.9
Environmental & Applied Solutions	244.6			227.2
Other	(111.1		)	(54.4		)
Total	$	723.8		$	743.0

Segment identifiable assets are shown below ($ in millions):



	March 29, 2019		December 31, 2018
Life Sciences	$	22,485.9	$	22,122.4
Diagnostics	14,282.8		14,031.1
Dental	6,019.5		5,897.3
Environmental & Applied Solutions	4,782.6		4,637.3
Other	4,203.6		1,144.4
Total	$	51,774.4	$	47,832.5

General (Policies)	3 Months Ended
General (Policies)	Mar. 29, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
New accounting standards	Accounting Standards Recently Adopted In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), which requires lessees to recognize a right-of-use (“ROU”) asset and a lease liability for all leases with terms greater than 12 months and also requires disclosures by lessees and lessors about the amount, timing and uncertainty of cash flows arising from leases. The accounting applied by a lessor is largely unchanged from that applied under the prior standard. Subsequent to the issuance of Topic 842, the FASB clarified the guidance through several ASUs; hereinafter the collection of lease guidance is referred to as “ASC 842”. On January 1, 2019, the Company adopted ASC 842 using the modified retrospective method for all lease arrangements at the beginning of the period of adoption. Results for reporting periods beginning January 1, 2019 are presented under ASC 842, while prior period amounts were not adjusted and continue to be reported in accordance with the Company’s historic accounting under ASC 840, Leases. The standard had a material impact on the Company’s Consolidated Condensed Balance Sheet but did not have a significant impact on the Company’s consolidated net earnings and cash flows. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases, while the accounting for finance leases remained substantially unchanged. For leases that commenced before the effective date of ASC 842, the Company elected the permitted practical expedients to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases. The Company also elected to include leases with a term of 12 months or less in the recognized ROU assets and lease liabilities. As a result of the cumulative impact of adopting ASC 842, the Company recorded operating lease ROU assets of $971 million and operating lease liabilities of $1,012 million as of January 1, 2019, primarily related to real estate and automobile leases, based on the present value of the future lease payments on the date of adoption. Refer to Note 5 for the additional disclosures required by ASC 842. The Company determines if an arrangement is a lease at inception. For leases where the Company is the lessee, ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also consists of any prepaid lease payments, lease incentives received, costs which will be incurred in exiting a lease and the amount of any asset or liability recognized on business combinations relating to favorable or unfavorable lease terms. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. The Company has lease agreements which require payments for lease and non-lease components and has elected to account for these as a single lease component. The Company leases Life Sciences, Diagnostics, and Environmental & Applied Solutions equipment to customers in both operating-type lease (“OTL”) and sales-type lease (“STL”) arrangements. Equipment lease revenue for OTL agreements is recognized on a straight-line basis over the life of the lease, and the costs of customer-leased equipment is recorded within property, plant and equipment, net in the accompanying Consolidated Condensed Balance Sheets and depreciated over the equipment’s estimated useful life. Depreciation expense associated with the leased equipment under OTL arrangements is reflected in cost of sales in the accompanying Consolidated Condensed Statements of Earnings. The OTLs are generally not cancellable until after an initial term and may or may not require the customer to purchase a minimum number of consumables or tests throughout the contract term. Certain of the Company’s lease contracts are customized for larger customers and often result in complex terms and conditions that typically require significant judgment in applying the criteria used to evaluate whether the arrangement should be considered an OTL or an STL. An STL results in earlier recognition of equipment revenue as compared to an OTL. Some of the Company’s leases include a purchase option for the customer to purchase the leased asset at the end of the lease arrangement for a purchase price equal to the asset’s fair market value at the time of the purchase. The Company manages its risk on the unguaranteed residual asset for leased equipment through the pricing and term of the leases. In certain geographies, equipment coming off OTL and STL arrangements after the initial lease term may be leased to other customers or used for spare parts. For lease arrangements with lease and non-lease components where the Company is the lessor, the Company allocates the contract’s transaction price to the lease and non-lease components on a relative standalone selling price basis using the Company’s best estimate of the standalone selling price of each distinct product or service in the contract. The primary method used to estimate standalone selling price is the price observed in standalone sales to customers; however, when prices in standalone sales are not available the Company may use third-party pricing for similar products or services or estimate the standalone selling price. Allocation of the transaction price is determined at the inception of the lease arrangement. The Company’s leases primarily consist of leases with fixed lease payments. For those leases with variable lease payments, the variable lease payment is typically based upon use of the leased equipment or the purchase of consumables used with the leased equipment. In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which expands and refines hedge accounting for both financial and non-financial risk components, aligns the recognition and presentation of the effects of hedging instruments and hedge items in the financial statements and includes certain targeted improvements to ease the application of current guidance related to the assessment of hedge effectiveness. The ASU is effective for public entities for fiscal years beginning after December 15, 2018. In January 2019, the Company entered into approximately $1.9 billion of cross-currency swap derivative contracts to hedge its net investment in foreign operations against adverse changes in the exchange rates between the U.S. dollar and the Danish kroner, Japanese yen, euro and the Swiss franc. Refer to Note 9 for additional disclosures about the Company’s hedging activities. Except for the above accounting policy for leases that was updated as a result of adopting ASC 842, there have been no changes to the Company’s significant accounting policies described in the Annual Report on Form 10-K for the year ended December 31, 2018 that have a material impact on the Company’s Consolidated Condensed Financial Statements and the related Notes. Accounting Standards Not Yet Adopted In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. The ASU is effective for public entities for fiscal years beginning after December 15, 2019, with early adoption permitted. In November 2018, the FASB issued ASU No. 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses, which provided additional implementation guidance on the previously issued ASU. Management has not yet completed its assessment of the impact of the new standard on the Company’s Consolidated Financial Statements. Currently, the Company believes that the most notable impact of this ASU will relate to its processes around the assessment of the adequacy of its allowance for doubtful accounts on trade accounts receivable and the recognition of credit losses. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820), which modifies the disclosures on fair value measurements by removing the requirement to disclose the amount and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy and the policy for timing of such transfers. The ASU expands the disclosure requirements for Level 3 fair value measurements, primarily focused on changes in unrealized gains and losses included in other comprehensive income (loss). The ASU is effective for public entities for fiscal years beginning after December 15, 2019, with early adoption permitted. Management has not yet completed its assessment of the impact of the new standard on the Company’s financial statements. In August 2018, the FASB issued ASU No. 2018-14, Disclosure Framework—Changes to the Disclosure Requirements for Defined Benefit Plans, which amends ASC 715 to add, remove, and clarify disclosure requirements related to defined benefit pension and other postretirement plans. The ASU is effective for public entities for fiscal years beginning after December 15, 2020, with early adoption permitted. Management has not yet completed its assessment of the impact of the new standard on the Company’s financial statements.

General (Tables)

3 Months Ended

Mar. 29, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Components Of Accumulated Other Comprehensive Income (Loss)

The changes in accumulated other comprehensive income (loss) by component are summarized below ($ in millions). Foreign currency translation adjustments generally relate to indefinite investments in non-U.S. subsidiaries, as well as the impact from the Company’s hedges of its net investment in foreign operations, including the Company’s cross-currency swap derivatives, net of any tax impacts.



	Foreign Currency Translation Adjustments			Pension & Postretirement Plan Benefit Adjustments				Unrealized Gain (Loss) on Available-For-Sale Securities Adjustments			Total
For the Three-Month Period Ended March 29, 2019:
Balance, December 31, 2018	$	(2,098.1	)	$	(691.1	)		$	(1.9	)	$	(2,791.1	)
Other comprehensive income (loss) before reclassifications:
(Decrease) increase	(7.3		)	—				0.5			(6.8		)
Income tax impact	(3.5		)	—				(0.1		)	(3.6		)
Other comprehensive income (loss) before reclassifications, net of income taxes	(10.8		)	—				0.4			(10.4		)
Amounts reclassified from accumulated other comprehensive income (loss):
Increase	—			7.1			(a)	—			7.1
Income tax impact	—			(1.7		)		—			(1.7		)
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes	—			5.4				—			5.4
Net current period other comprehensive income (loss), net of income taxes	(10.8		)	5.4				0.4			(5.0		)
Balance, March 29, 2019	$	(2,108.9	)	$	(685.7	)		$	(1.5	)	$	(2,796.1	)
For the Three-Month Period Ended March 30, 2018:
Balance, December 31, 2017	$	(1,422.1	)	$	(571.2	)		$	(0.9	)	$	(1,994.2	)
Adoption of accounting standards	(43.8		)	(107.2		)		(0.2		)	(151.2		)
Balance, January 1, 2018	(1,465.9		)	(678.4		)		(1.1		)	(2,145.4		)
Other comprehensive income (loss) before reclassifications:
Increase (decrease)	294.1			—				(0.8		)	293.3
Income tax impact	—			—				0.3			0.3
Other comprehensive income (loss) before reclassifications, net of income taxes	294.1			—				(0.5		)	293.6
Amounts reclassified from accumulated other comprehensive income (loss):
Increase	—			9.3			(a)	—			9.3
Income tax impact	—			(2.2		)		—			(2.2		)
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes	—			7.1				—			7.1
Net current period other comprehensive income (loss), net of income taxes	294.1			7.1				(0.5		)	300.7
Balance, March 30, 2018	$	(1,171.8	)	$	(671.3	)		$	(1.6	)	$	(1,844.7	)

^(a) This accumulated other comprehensive income (loss) component is included in the computation of net periodic pension cost. Refer to Note 10 for additional details.

Revenue (Tables)

3 Months Ended

Mar. 29, 2019

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue



	Three-Month Period Ended March 29, 2019
	Life Sciences		Diagnostics		Dental		Environmental & Applied Solutions		Total
Geographical region:
North America	$	587.3	$	632.4	$	298.5	$	449.2	$	1,967.4
Western Europe	460.3		288.9		160.1		259.7		1,169.0
Other developed markets	149.3		92.0		40.4		28.9		310.6
High-growth markets	430.0		523.5		160.7		318.7		1,432.9
Total	$	1,626.9	$	1,536.8	$	659.7	$	1,056.5	$	4,879.9

Revenue type:
Recurring	$	1,068.2	$	1,324.1	$	487.8	$	582.2	$	3,462.3
Nonrecurring	558.7		212.7		171.9		474.3		1,417.6
Total	$	1,626.9	$	1,536.8	$	659.7	$	1,056.5	$	4,879.9



	Three-Month Period Ended March 30, 2018
	Life Sciences		Diagnostics		Dental		Environmental & Applied Solutions		Total
Geographical region:
North America	$	480.4	$	607.4	$	291.3	$	418.3	$	1,797.4
Western Europe	449.9		310.4		175.6		264.8		1,200.7
Other developed markets	144.9		92.2		43.9		31.6		312.6
High-growth markets	400.8		509.7		161.8		312.4		1,384.7
Total	$	1,476.0	$	1,519.7	$	672.6	$	1,027.1	$	4,695.4

Revenue type:
Recurring	$	970.4	$	1,308.5	$	488.0	$	557.0	$	3,323.9
Nonrecurring	505.6		211.2		184.6		470.1		1,371.5
Total	$	1,476.0	$	1,519.7	$	672.6	$	1,027.1	$	4,695.4

Acquisitions (Tables)

3 Months Ended

Mar. 29, 2019

Business Combinations [Abstract]

Fair Values Of The Assets Acquired And Liabilities Assumed



Trade accounts receivable	$	7.7
Inventories	8.6
Property, plant and equipment	3.9
Goodwill	211.1
Other intangible assets, primarily customer relationships, trade names and technology	87.0
Trade accounts payable	(2.6		)
Other assets and liabilities, net	(7.5		)
Net cash consideration	$	308.2

Results Of Operations If Acquisition Was Consummated

The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have been achieved had the acquisitions been consummated as of that time ($ in millions, except per share amounts):



	Three-Month Period Ended
	March 29, 2019		March 30, 2018
Sales	$	4,884.1	$	4,788.3
Net earnings attributable to common stockholders	326.1		552.4
Diluted net earnings per share	0.45		0.78

Leases (Tables)

3 Months Ended

Mar. 29, 2019

Leases [Abstract]

Lessee, Components of Lease Expense

For the three-month period ended March 29, 2019, the components of operating lease expense were as follows ($ in millions):



Fixed operating lease expense ^(a)	$	63.4
Variable operating lease expense	12.0
Total operating lease expense	$	75.4

^(a)Includes short-term leases and sublease income, both of which were immaterial.

Lessee, Cash Flow

Supplemental cash flow information related to the Company’s operating leases for the three-month period ended March 29, 2019 was as follows ($ in millions):



Cash paid for amounts included in the measurement of operating lease liabilities	$	61.9
ROU assets obtained in exchange for operating lease obligations	39.6

Lessee, Assets and Liabilities



Lease Assets and Liabilities	Classification
Assets:
Operating lease ROU assets	Other long-term assets	$	946.7

Liabilities:
Current:
Operating lease liabilities	Accrued expenses and other liabilities	$	186.1
Long-term:
Operating lease liabilities	Other long-term liabilities	800.0
Total operating lease liabilities		$	986.1

Weighted average remaining lease term		7 years
Weighted average discount rate		3.3		%

Lessee, Operating Lease, Liability, Maturity

The following table presents the maturity of the Company’s operating lease liabilities as of March 29, 2019 ($ in millions):



Remainder of 2019	$	163.3
2020	183.5
2021	149.0
2022	125.8
2023	109.7
Thereafter	395.3
Total operating lease payments	1,126.6
Less: imputed interest	140.5
Total operating lease liabilities	$	986.1

Goodwill (Tables)

3 Months Ended

Mar. 29, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Rollforward Of Goodwill

The following is a rollforward of the Company’s goodwill ($ in millions):



Balance, December 31, 2018	$	25,906.0
Attributable to 2019 acquisitions	211.1
Adjustments due to finalization of purchase price allocations	(6.1		)
Foreign currency translation and other	(109.6		)
Balance, March 29, 2019	$	26,001.4

The carrying value of goodwill by segment is summarized as follows ($ in millions):



	March 29, 2019		December 31, 2018
Life Sciences	$	13,463.0	$	13,311.0
Diagnostics	6,902.9		6,925.6
Dental	3,301.0		3,325.5
Environmental & Applied Solutions	2,334.5		2,343.9
Total	$	26,001.4	$	25,906.0

Fair Value Measurements (Tables)

3 Months Ended

Mar. 29, 2019

Fair Value Disclosures [Abstract]

Financial Assets And Liabilities Carried At Fair Value

A summary of financial assets and liabilities that are measured at fair value on a recurring basis were as follows ($ in millions):



	Quoted Prices in Active Market (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
March 29, 2019:
Assets:
Available-for-sale debt securities	$	—	$	36.8	$	—	$	36.8
Investment in equity securities	—		—		193.1		193.1
Cross-currency swap derivative contracts	—		17.1		—		17.1
Liabilities:
Cross-currency swap derivative contracts	—		2.3		—		2.3
Deferred compensation plans	—		66.3		—		66.3

December 31, 2018:
Assets:
Available-for-sale debt securities	$	—	$	38.3	$	—	$	38.3
Investment in equity securities	—		—		148.9		148.9
Liabilities:
Deferred compensation plans	—		60.9		—		60.9

Carrying Amounts And Fair Values Of Financial Instruments

The carrying amounts and fair values of the Company’s financial instruments were as follows ($ in millions):



	March 29, 2019				December 31, 2018
	Carrying Amount		Fair Value		Carrying Amount		Fair Value
Assets:
Available-for-sale debt securities	$	36.8	$	36.8	$	38.3	$	38.3
Investment in equity securities	193.1		193.1		148.9		148.9
Cross-currency swap derivative contracts	17.1		17.1		—		—
Liabilities:
Cross-currency swap derivative contracts	2.3		2.3		—		—
Notes payable and current portion of long-term debt	36.6		36.6		51.8		51.8
Long-term debt	9,458.2		9,848.5		9,688.5		9,990.6

Financing (Tables)

3 Months Ended

Mar. 29, 2019

Debt Disclosure [Abstract]

Components Of Debt

The components of the Company’s debt were as follows ($ in millions):



	March 29, 2019		December 31, 2018
U.S. dollar-denominated commercial paper	$	—	$	72.8
Euro-denominated commercial paper (€2.1 billion and €2.1 billion, respectively)	2,327.0		2,377.5
1.0% senior unsecured notes due 2019 (€600.0 million aggregate principal amount) (the “2019 Euronotes”)	672.7		687.0
2.4% senior unsecured notes due 2020	498.7		498.5
5.0% senior unsecured notes due 2020 (the “2020 Assumed Pall Notes”)	386.6		386.7
Zero-coupon LYONs due 2021	44.3		56.2
0.352% senior unsecured notes due 2021 (¥30.0 billion aggregate principal amount) (the “2021 Yen Notes”)	270.2		273.2
1.7% senior unsecured notes due 2022 (€800.0 million aggregate principal amount) (the “2022 Euronotes”)	894.1		913.2
Floating rate senior unsecured notes due 2022 (€250.0 million aggregate principal amount) (the “Floating Rate 2022 Euronotes”)	279.7		285.7
0.5% senior unsecured bonds due 2023 (CHF 540.0 million aggregate principal amount) (the “2023 CHF Bonds”)	543.4		550.7
2.5% senior unsecured notes due 2025 (€800.0 million aggregate principal amount) (the “2025 Euronotes”)	893.4		912.6
3.35% senior unsecured notes due 2025	496.9		496.8
0.3% senior unsecured notes due 2027 (¥30.8 billion aggregate principal amount) (the “2027 Yen Notes”)	276.9		279.9
1.2% senior unsecured notes due 2027 (€600.0 million aggregate principal amount) (the “2027 Euronotes”)	667.6		682.0
1.125% senior unsecured bonds due 2028 (CHF 210.0 million aggregate principal amount) (the “2028 CHF Bonds”)	215.2		218.1
0.65% senior unsecured notes due 2032 (¥53.2 billion aggregate principal amount) (the “2032 Yen Notes”)	478.1		483.4
4.375% senior unsecured notes due 2045	499.4		499.3
Other	50.6		66.7
Total debt	9,494.8		9,740.3
Less: currently payable	36.6		51.8
Long-term debt	$	9,458.2	$	9,688.5

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

Hedging Transactions And Derivative Financial Instruments (Tables)

3 Months Ended

Mar. 29, 2019

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments, Gain (Loss) [Table Text Block]

The following table summarizes the notional values and pretax impact of changes in the fair values of instruments designated as net investment hedges ($ in millions):



	Three-Month Period Ended March 29, 2019
	Notional Amount		Gain (Loss) Recognized in OCI
Foreign currency contracts	$	1,875.0	$	14.8
Foreign currency denominated debt	7,518.3		137.8
Total	$	9,393.3	$	152.6

Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]

The following table summarizes the notional values and pretax impact of changes in the fair values of instruments designated as net investment hedges ($ in millions):



	Three-Month Period Ended March 29, 2019
	Notional Amount		Gain (Loss) Recognized in OCI
Foreign currency contracts	$	1,875.0	$	14.8
Foreign currency denominated debt	7,518.3		137.8
Total	$	9,393.3	$	152.6

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value



	March 29, 2019
Derivative assets:
Prepaid expenses and other current assets	$	17.1

Derivative liabilities:
Accrued expenses and other liabilities	2.3

Nonderivative hedging instruments:
Long-term debt	7,518.3

Defined Benefit Plans (Tables)

3 Months Ended

Mar. 29, 2019

Defined Benefit Plan Disclosure [Line Items]

Schedule of Defined Benefit Plans Disclosures



	Three-Month Period Ended
	March 29, 2019			March 30, 2018
Service cost:
Cost of sales	$	(2.0	)	$	(2.1	)
Selling, general and administrative expenses	(7.8		)	(8.8		)
Total service cost	(9.8		)	(10.9		)
Other net periodic benefit costs:
Other income, net	5.2			7.8
Total	$	(4.6	)	$	(3.1	)

Defined benefit pension plans

Defined Benefit Plan Disclosure [Line Items]

Schedule of Net Benefit Costs

The following sets forth the components of the Company’s net periodic benefit cost of the noncontributory defined benefit pension plans ($ in millions):



	Three-Month Period Ended
	March 29, 2019			March 30, 2018
U.S. pension benefits:
Service cost	$	(1.6	)	$	(2.1	)
Interest cost	(22.3		)	(20.2		)
Expected return on plan assets	31.6			33.1
Amortization of actuarial loss	(6.3		)	(7.8		)
Amortization of prior service cost	(0.2		)	(0.3		)
Net periodic pension benefit	$	1.2		$	2.7

Non-U.S. pension benefits:
Service cost	$	(8.1	)	$	(8.7	)
Interest cost	(6.7		)	(6.7		)
Expected return on plan assets	10.9			12.1
Amortization of actuarial gain (loss)	0.1			(1.5		)
Amortization of prior service (cost) credit	(1.2		)	0.1
Settlement loss recognized	—			(0.4		)
Net periodic pension cost	$	(5.0	)	$	(5.1	)

Other postretirement benefit plans

Defined Benefit Plan Disclosure [Line Items]

Schedule of Net Benefit Costs

The following sets forth the components of the Company’s net periodic benefit cost of the other postretirement employee benefit plans ($ in millions):



	Three-Month Period Ended
	March 29, 2019			March 30, 2018
Service cost	$	(0.1	)	$	(0.1	)
Interest cost	(1.2		)	(1.2		)
Amortization of prior service credit	0.5			0.6
Net periodic cost	$	(0.8	)	$	(0.7	)

Income Taxes (Table) (Tables)

3 Months Ended

Mar. 29, 2019

Income Tax Disclosure [Abstract]

Summary Of Effective Income Tax Rate

The following table summarizes the Company’s effective tax rate:



	Three-Month Period Ended
	March 29, 2019		March 30, 2018
Effective tax rate	53.7	%	20.5	%

Commitments And Contingencies (Tables)

3 Months Ended

Mar. 29, 2019

Commitments and Contingencies Disclosure [Abstract]

Warranty Accrual

The following is a rollforward of the Company’s accrued warranty liability ($ in millions):



Balance, December 31, 2018	$	77.4
Accruals for warranties issued during the period	18.0
Settlements made	(17.2		)
Effect of foreign currency translation	(0.2		)
Balance, March 29, 2019	$	78.0

Stock Transactions And Stock-Based Compensation (Tables)

3 Months Ended

Mar. 29, 2019

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Components Of Stock-Based Compensation Program

The following summarizes the components of the Company’s stock-based compensation expense ($ in millions):



	Three-Month Period Ended
	March 29, 2019			March 30, 2018
Restricted stock units (“RSUs”)/performance stock units (“PSUs”):
Pretax compensation expense	$	24.3		$	20.9
Income tax benefit	(5.1		)	(4.4		)
RSU/PSU expense, net of income taxes	19.2			16.5
Stock options:
Pretax compensation expense	14.9			12.4
Income tax benefit	(3.2		)	(2.6		)
Stock option expense, net of income taxes	11.7			9.8
Total stock-based compensation:
Pretax compensation expense	39.2			33.3
Income tax benefit	(8.3		)	(7.0		)
Total stock-based compensation expense, net of income taxes	$	30.9		$	26.3

Net Earnings Per Share (Tables)

3 Months Ended

Mar. 29, 2019

Earnings Per Share [Abstract]

Components Of Basic And Diluted Earnings Per Share

Information related to the calculation of net earnings per share is summarized as follows ($ and shares in millions, except per share amounts):



	Three-Month Period Ended
	March 29, 2019			March 30, 2018
Numerator:
Net earnings	$	333.8		$	566.6
Adjustment for interest on convertible debentures	0.5			0.6
MCPS dividends	(6.5		)	—
Net earnings attributable to common stockholders after assumed conversions for diluted EPS	$	327.8		$	567.2

Denominator:
Weighted average common shares outstanding used in basic EPS	707.6			698.6
Incremental common shares from:
Assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs	8.7			8.3
Assumed conversion of the convertible debentures	2.2			2.6
Weighted average common shares outstanding used in diluted EPS	718.5			709.5

Basic EPS	$	0.46		$	0.81
Diluted EPS	$	0.46		$	0.80

Segment Information (Tables)

3 Months Ended

Mar. 29, 2019

Segment Reporting [Abstract]

Segment Results

Segment results are shown below ($ in millions):



	Three-Month Period Ended
	March 29, 2019			March 30, 2018
Sales:
Life Sciences	$	1,626.9		$	1,476.0
Diagnostics	1,536.8			1,519.7
Dental	659.7			672.6
Environmental & Applied Solutions	1,056.5			1,027.1
Total	$	4,879.9		$	4,695.4

Operating profit:
Life Sciences	$	309.0		$	271.3
Diagnostics	233.1			248.0
Dental	48.2			50.9
Environmental & Applied Solutions	244.6			227.2
Other	(111.1		)	(54.4		)
Total	$	723.8		$	743.0

Segment identifiable assets are shown below ($ in millions):



	March 29, 2019		December 31, 2018
Life Sciences	$	22,485.9	$	22,122.4
Diagnostics	14,282.8		14,031.1
Dental	6,019.5		5,897.3
Environmental & Applied Solutions	4,782.6		4,637.3
Other	4,203.6		1,144.4
Total	$	51,774.4	$	47,832.5

General (Narrative) (Details) - USD ($) $ in Millions	Mar. 29, 2019	Jan. 31, 2019	Jan. 01, 2019
Operating lease ROU assets	$ 946.7		$ 971.0
Total operating lease liabilities	986.1		$ 1,012.0
Net investment hedging
Derivative, notional amount	9,393.3
Net investment hedging \| Foreign currency contracts
Derivative, notional amount	$ 1,875.0	$ 1,900.0

General (Components of Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Millions		3 Months Ended
	Jan. 01, 2018	Mar. 29, 2019	Mar. 30, 2018
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance		$ (2,791.1)
Adoption of accounting standards	$ (151.2)
Total other comprehensive income (loss), net of income taxes		(5.0)	$ 300.7
Ending balance	(2,145.4)	(2,796.1)
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	(1,422.1)	(2,098.1)	(1,422.1)
Adoption of accounting standards	(43.8)
Increase (decrease)		(7.3)	294.1
Income tax impact		(3.5)	0.0
Other comprehensive income (loss) before reclassifications, net of income taxes		(10.8)	294.1
Increase (decrease)		0.0	0.0
Income tax impact		0.0	0.0
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes		0.0	0.0
Total other comprehensive income (loss), net of income taxes		(10.8)	294.1
Ending balance	(1,465.9)	(2,108.9)	(1,171.8)
Pension & Postretirement Plan Benefit Adjustments
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	(571.2)	(691.1)	(571.2)
Adoption of accounting standards	(107.2)
Increase (decrease)		0.0	0.0
Income tax impact		0.0	0.0
Other comprehensive income (loss) before reclassifications, net of income taxes		0.0	0.0
Increase (decrease)		7.1	9.3
Income tax impact		(1.7)	(2.2)
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes		5.4	7.1
Total other comprehensive income (loss), net of income taxes		5.4	7.1
Ending balance	(678.4)	(685.7)	(671.3)
Unrealized Gain (Loss) on Available-For-Sale Securities Adjustments
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	(0.9)	(1.9)	(0.9)
Adoption of accounting standards	(0.2)
Increase (decrease)		0.5	(0.8)
Income tax impact		(0.1)	0.3
Other comprehensive income (loss) before reclassifications, net of income taxes		0.4	(0.5)
Increase (decrease)		0.0	0.0
Income tax impact		0.0	0.0
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes		0.0	0.0
Total other comprehensive income (loss), net of income taxes		0.4	(0.5)
Ending balance	(1.1)	(1.5)	(1.6)
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	$ (1,994.2)	(2,791.1)	(1,994.2)
Increase (decrease)		(6.8)	293.3
Income tax impact		(3.6)	0.3
Other comprehensive income (loss) before reclassifications, net of income taxes		(10.4)	293.6
Increase (decrease)		7.1	9.3
Income tax impact		(1.7)	(2.2)
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes		5.4	7.1
Total other comprehensive income (loss), net of income taxes		(5.0)	300.7
Ending balance		$ (2,796.1)	$ (1,844.7)

Revenue (Narrative) (Details) - USD ($) $ in Millions		3 Months Ended
Revenue (Narrative) (Details) - USD ($) $ in Millions	Mar. 29, 2019	Mar. 29, 2019	Mar. 30, 2018	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
Revenue, OTLs and STLs		$ 107	$ 97
Revenue, remaining performance obligation	$ 1,900	1,900
Revenue, remaining performance obligation, expected satisfaction in next 12 months, percent	43.00%
Revenue, remaining performance obligation, expected satisfaction in subsequent 12 months, percent	27.00%
Contract with customer, asset, net	$ 97	97		$ 82
Contract with customer, liability	$ 838	838		$ 799
Contract with customer, liability, revenue recognized		$ 287	$ 265

Revenue (Disaggregation of Revenue by Geographical Region) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2019	Mar. 30, 2018
Disaggregation of Revenue [Line Items]
Sales	$ 4,879.9	$ 4,695.4
North America
Disaggregation of Revenue [Line Items]
Sales	1,967.4	1,797.4
Western Europe
Disaggregation of Revenue [Line Items]
Sales	1,169.0	1,200.7
Other developed markets
Disaggregation of Revenue [Line Items]
Sales	310.6	312.6
High-growth markets
Disaggregation of Revenue [Line Items]
Sales	1,432.9	1,384.7
Operating segments \| Life Sciences
Disaggregation of Revenue [Line Items]
Sales	1,626.9	1,476.0
Operating segments \| Life Sciences \| North America
Disaggregation of Revenue [Line Items]
Sales	587.3	480.4
Operating segments \| Life Sciences \| Western Europe
Disaggregation of Revenue [Line Items]
Sales	460.3	449.9
Operating segments \| Life Sciences \| Other developed markets
Disaggregation of Revenue [Line Items]
Sales	149.3	144.9
Operating segments \| Life Sciences \| High-growth markets
Disaggregation of Revenue [Line Items]
Sales	430.0	400.8
Operating segments \| Diagnostics
Disaggregation of Revenue [Line Items]
Sales	1,536.8	1,519.7
Operating segments \| Diagnostics \| North America
Disaggregation of Revenue [Line Items]
Sales	632.4	607.4
Operating segments \| Diagnostics \| Western Europe
Disaggregation of Revenue [Line Items]
Sales	288.9	310.4
Operating segments \| Diagnostics \| Other developed markets
Disaggregation of Revenue [Line Items]
Sales	92.0	92.2
Operating segments \| Diagnostics \| High-growth markets
Disaggregation of Revenue [Line Items]
Sales	523.5	509.7
Operating segments \| Dental
Disaggregation of Revenue [Line Items]
Sales	659.7	672.6
Operating segments \| Dental \| North America
Disaggregation of Revenue [Line Items]
Sales	298.5	291.3
Operating segments \| Dental \| Western Europe
Disaggregation of Revenue [Line Items]
Sales	160.1	175.6
Operating segments \| Dental \| Other developed markets
Disaggregation of Revenue [Line Items]
Sales	40.4	43.9
Operating segments \| Dental \| High-growth markets
Disaggregation of Revenue [Line Items]
Sales	160.7	161.8
Operating segments \| Environmental & Applied Solutions
Disaggregation of Revenue [Line Items]
Sales	1,056.5	1,027.1
Operating segments \| Environmental & Applied Solutions \| North America
Disaggregation of Revenue [Line Items]
Sales	449.2	418.3
Operating segments \| Environmental & Applied Solutions \| Western Europe
Disaggregation of Revenue [Line Items]
Sales	259.7	264.8
Operating segments \| Environmental & Applied Solutions \| Other developed markets
Disaggregation of Revenue [Line Items]
Sales	28.9	31.6
Operating segments \| Environmental & Applied Solutions \| High-growth markets
Disaggregation of Revenue [Line Items]
Sales	$ 318.7	$ 312.4

Revenue (Disaggregation of Revenue by Revenue Type) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2019	Mar. 30, 2018
Disaggregation of Revenue [Line Items]
Sales	$ 4,879.9	$ 4,695.4
Recurring revenue
Disaggregation of Revenue [Line Items]
Sales	3,462.3	3,323.9
Nonrecurring revenue
Disaggregation of Revenue [Line Items]
Sales	1,417.6	1,371.5
Operating segments \| Life Sciences
Disaggregation of Revenue [Line Items]
Sales	1,626.9	1,476.0
Operating segments \| Life Sciences \| Recurring revenue
Disaggregation of Revenue [Line Items]
Sales	1,068.2	970.4
Operating segments \| Life Sciences \| Nonrecurring revenue
Disaggregation of Revenue [Line Items]
Sales	558.7	505.6
Operating segments \| Diagnostics
Disaggregation of Revenue [Line Items]
Sales	1,536.8	1,519.7
Operating segments \| Diagnostics \| Recurring revenue
Disaggregation of Revenue [Line Items]
Sales	1,324.1	1,308.5
Operating segments \| Diagnostics \| Nonrecurring revenue
Disaggregation of Revenue [Line Items]
Sales	212.7	211.2
Operating segments \| Dental
Disaggregation of Revenue [Line Items]
Sales	659.7	672.6
Operating segments \| Dental \| Recurring revenue
Disaggregation of Revenue [Line Items]
Sales	487.8	488.0
Operating segments \| Dental \| Nonrecurring revenue
Disaggregation of Revenue [Line Items]
Sales	171.9	184.6
Operating segments \| Environmental & Applied Solutions
Disaggregation of Revenue [Line Items]
Sales	1,056.5	1,027.1
Operating segments \| Environmental & Applied Solutions \| Recurring revenue
Disaggregation of Revenue [Line Items]
Sales	582.2	557.0
Operating segments \| Environmental & Applied Solutions \| Nonrecurring revenue
Disaggregation of Revenue [Line Items]
Sales	$ 474.3	$ 470.1

Acquisitions (Narrative) (Details) $ in Millions	3 Months Ended
Acquisitions (Narrative) (Details) $ in Millions	Mar. 29, 2019 USD ($) Business
Business Combinations [Abstract]
Number of businesses acquired \| Business	1
Net cash consideration	$ 308.2
Revenue reported by acquired entity for last annual period	61.0
Goodwill	$ 211.1

Acquisitions (Fair Values Of The Assets Acquired And Liabilities) (Details) $ in Millions	3 Months Ended
	Mar. 29, 2019 USD ($)
Business Combinations [Abstract]
Trade accounts receivable	$ 7.7
Inventories	8.6
Property, plant and equipment	3.9
Goodwill	211.1
Other intangible assets, primarily customer relationships, trade names and technology	87.0
Trade accounts payable	(2.6)
Other assets and liabilities, net	(7.5)
Net cash consideration	$ 308.2

Acquisitions (Pro Forma Financial Information) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 29, 2019	Mar. 30, 2018
Business Combinations [Abstract]
Sales	$ 4,884.1	$ 4,788.3
Net earnings attributable to common stockholders	$ 326.1	$ 552.4
Diluted net earnings per share	$ 0.45	$ 0.78

Acquisitions (Pending Acquisition) (Narrative) (Details) - USD ($) $ in Millions			3 Months Ended
	Mar. 01, 2019	Feb. 25, 2019	Mar. 29, 2019
Business Acquisition [Line Items]
Pending acquisition, purchase price			$ 308.2
Pending acquisition, revenue for last annual period			$ 61.0
Biopharma Acquisition
Business Acquisition [Line Items]
Pending acquisition, purchase price		$ 21,000.0
Pending acquisition, pension liabilities to be assumed		400.0
Pending acquisition, revenue for last annual period		$ 3,000.0
Proceeds from issuance of common stock and preferred stock	$ 3,000.0

Leases (Lease Arrangements) (Narrative) (Details)	3 Months Ended
Leases (Lease Arrangements) (Narrative) (Details)	Mar. 29, 2019
Lessee, Lease, Description [Line Items]
Lessee, operating lease, option to terminate, term	30 days
Maximum
Lessee, Lease, Description [Line Items]
Lessee, operating lease, renewal term	30 years

Leases (Components of Lease Expense) (Details) $ in Millions	3 Months Ended
	Mar. 29, 2019 USD ($)
Leases [Abstract]
Fixed operating lease expense	$ 63.4
Variable operating lease expense	12.0
Total operating lease expense	$ 75.4

Leases (Supplemental Cash Flow Information) (Details) $ in Millions	3 Months Ended
	Mar. 29, 2019 USD ($)
Leases [Abstract]
Cash paid for amounts included in the measurement of operating lease liabilities	$ 61.9
ROU assets obtained in exchange for operating lease obligations	$ 39.6

Leases (Supplemental Balance Sheet Inofrmation) (Details) - USD ($) $ in Millions	Mar. 29, 2019	Jan. 01, 2019
Leases [Abstract]
Operating lease ROU assets	$ 946.7	$ 971.0
Operating lease liabilities, current	186.1
Operating lease liabilities, long-term	800.0
Total operating lease liabilities	$ 986.1	$ 1,012.0
Weighted average remaining lease term	7 years
Weighted average discount rate	3.30%

Leases (Maturities of Lease Liabilities) (Details) - USD ($) $ in Millions	Mar. 29, 2019	Jan. 01, 2019
Operating Lease Liabilities, Payments Due [Abstract]
Remainder of fiscal year	$ 163.3
Due in year two	183.5
Due in year three	149.0
Due in year four	125.8
Due in year five	109.7
Due thereafter	395.3
Total operating lease payments	1,126.6
Less: imputed interest	140.5
Total operating lease liabilities	$ 986.1	$ 1,012.0

Goodwill (Rollforward of Goodwill) (Details) $ in Millions	3 Months Ended
Goodwill (Rollforward of Goodwill) (Details) $ in Millions	Mar. 29, 2019 USD ($)
Goodwill [Roll Forward]
Balance, December 31, 2018	$ 25,906.0
Attributable to 2019 acquisitions	211.1
Adjustments due to finalization of purchase price allocations	(6.1)
Foreign currency translation and other	(109.6)
Balance, March 29, 2019	$ 26,001.4

Goodwill (Goodwill by Segment) (Details) - USD ($) $ in Millions	Mar. 29, 2019	Dec. 31, 2018
Goodwill [Line Items]
Total goodwill	$ 26,001.4	$ 25,906.0
Operating segments \| Life Sciences
Goodwill [Line Items]
Total goodwill	13,463.0	13,311.0
Operating segments \| Diagnostics
Goodwill [Line Items]
Total goodwill	6,902.9	6,925.6
Operating segments \| Dental
Goodwill [Line Items]
Total goodwill	3,301.0	3,325.5
Operating segments \| Environmental & Applied Solutions
Goodwill [Line Items]
Total goodwill	$ 2,334.5	$ 2,343.9

Fair Value Measurements (Financial Assets and Liabilities Carried at Fair Value) (Details) - USD ($) $ in Millions	Mar. 29, 2019	Dec. 31, 2018
Assets:
Available-for-sale debt securities	$ 36.8	$ 38.3
Investment in equity securities	193.1	148.9
Cross-currency swap derivative contracts	17.1
Liabilities:
Cross-currency swap derivative contracts	2.3
Deferred compensation plans	66.3	60.9
Quoted Prices in Active Market (Level 1)
Assets:
Available-for-sale debt securities	0.0	0.0
Investment in equity securities	0.0	0.0
Cross-currency swap derivative contracts	0.0
Liabilities:
Cross-currency swap derivative contracts	0.0
Deferred compensation plans	0.0	0.0
Significant Other Observable Inputs (Level 2)
Assets:
Available-for-sale debt securities	36.8	38.3
Investment in equity securities	0.0	0.0
Cross-currency swap derivative contracts	17.1
Liabilities:
Cross-currency swap derivative contracts	2.3
Deferred compensation plans	66.3	60.9
Significant Unobservable Inputs (Level 3)
Assets:
Available-for-sale debt securities	0.0	0.0
Investment in equity securities	193.1	148.9
Cross-currency swap derivative contracts	0.0
Liabilities:
Cross-currency swap derivative contracts	0.0
Deferred compensation plans	$ 0.0	$ 0.0

Fair Value Measurements (Carrying Amounts and Fair Values of Financial Instruments) (Details) - USD ($) $ in Millions	Mar. 29, 2019	Dec. 31, 2018
Assets:
Available-for-sale debt securities	$ 36.8	$ 38.3
Investment in equity securities	193.1	148.9
Cross-currency swap derivative contracts	17.1
Liabilities:
Cross-currency swap derivative contracts	2.3
Carrying Amount
Assets:
Available-for-sale debt securities	36.8	38.3
Investment in equity securities	193.1	148.9
Cross-currency swap derivative contracts	17.1	0.0
Liabilities:
Cross-currency swap derivative contracts	2.3	0.0
Notes payable and current portion of long-term debt	36.6	51.8
Long-term debt	9,458.2	9,688.5
Fair Value
Assets:
Available-for-sale debt securities	36.8	38.3
Investment in equity securities	193.1	148.9
Cross-currency swap derivative contracts	17.1	0.0
Liabilities:
Cross-currency swap derivative contracts	2.3	0.0
Notes payable and current portion of long-term debt	36.6	51.8
Long-term debt	$ 9,848.5	$ 9,990.6

Financing (Narrative) (Details) $ / shares in Units, shares in Thousands, € in Millions		3 Months Ended
	Jun. 29, 2018	Mar. 29, 2019 USD ($) $ / shares shares	Mar. 30, 2018 USD ($)	Mar. 29, 2019 EUR (€)	Dec. 31, 2018 USD ($) $ / shares	Dec. 31, 2018 EUR (€)
Debt Instrument [Line Items]
Long-term debt		$ 9,494,800,000			$ 9,740,300,000
Debt discounts, premiums and debt issuance costs		$ 17,000,000			$ 19,000,000
Common stock, par value \| $ / shares		$ 0.01			$ 0.01
Debt conversion, converted instrument, tax benefit		$ 4,700,000	$ 3,100,000
Euro-denominated commercial paper \| Commercial paper
Debt Instrument [Line Items]
Weighted average interest rate of long-term debt, interest rate		(0.30%)		(0.30%)
Weighted average maturity of long-term debt, at point in time	37 days
Long-term debt		$ 2,327,000,000		€ 2,100.0	$ 2,377,500,000	€ 2,100.0
U.S. dollar-denominated commercial paper \| Commercial paper
Debt Instrument [Line Items]
Long-term debt		0			72,800,000
1.0% senior unsecured notes due 2019 \| Senior notes
Debt Instrument [Line Items]
Long-term debt		672,700,000			687,000,000
Debt instrument, face value		673,000,000		€ 600.0		€ 600.0
Zero-coupon LYONs due 2021 \| Convertible debt
Debt Instrument [Line Items]
Long-term debt		$ 44,300,000			$ 56,200,000
Shares issued under debt conversion, shares \| shares		486
Debt conversion, converted instrument, tax benefit		$ 5,000,000
Revolving credit facility \| Credit facility \| Long-term debt
Debt Instrument [Line Items]
Line of credit		4,000,000,000
Line of credit facility, amount outstanding		$ 0

Financing (Components Of Debt) (Details) € in Millions, SFr in Millions, ¥ in Billions	Mar. 29, 2019 CHF (SFr)	Mar. 29, 2019 JPY (¥)	Mar. 29, 2019 USD ($)	Mar. 29, 2019 EUR (€)	Dec. 31, 2018 CHF (SFr)	Dec. 31, 2018 JPY (¥)	Dec. 31, 2018 USD ($)	Dec. 31, 2018 EUR (€)
Debt Instrument [Line Items]
Long-term debt			$ 9,494,800,000				$ 9,740,300,000
Less: currently payable			36,600,000				51,800,000
Long-term debt excluding currently payable			9,458,200,000				9,688,500,000
Other
Debt Instrument [Line Items]
Long-term debt			50,600,000				66,700,000
Commercial paper \| U.S. dollar-denominated commercial paper
Debt Instrument [Line Items]
Long-term debt			0				72,800,000
Commercial paper \| Euro-denominated commercial paper
Debt Instrument [Line Items]
Long-term debt			2,327,000,000	€ 2,100.0			2,377,500,000	€ 2,100.0
Senior notes \| 1.0% senior unsecured notes due 2019
Debt Instrument [Line Items]
Long-term debt			$ 672,700,000				687,000,000
Interest rate of debt instrument	1.00%	1.00%	1.00%	1.00%
Debt instrument, face value			$ 673,000,000	€ 600.0				600.0
Senior notes \| 2.4% senior unsecured notes due 2020
Debt Instrument [Line Items]
Long-term debt			$ 498,700,000				498,500,000
Interest rate of debt instrument	2.40%	2.40%	2.40%	2.40%
Senior notes \| 5.0% senior notes due 2020
Debt Instrument [Line Items]
Long-term debt			$ 386,600,000				386,700,000
Interest rate of debt instrument	5.00%	5.00%	5.00%	5.00%
Senior notes \| 0.352% senior unsecured notes due 2021
Debt Instrument [Line Items]
Long-term debt			$ 270,200,000				273,200,000
Interest rate of debt instrument	0.352%	0.352%	0.352%	0.352%
Debt instrument, face value \| ¥		¥ 30.0				¥ 30.0
Senior notes \| 1.7% senior unsecured notes due 2022
Debt Instrument [Line Items]
Long-term debt			$ 894,100,000				913,200,000
Interest rate of debt instrument	1.70%	1.70%	1.70%	1.70%
Debt instrument, face value \| €				€ 800.0				800.0
Senior notes \| Floating rate senior unsecured notes due 2022
Debt Instrument [Line Items]
Long-term debt			$ 279,700,000				285,700,000
Debt instrument, face value \| €				€ 250.0				250.0
Senior notes \| 2.5% senior unsecured notes due 2025
Debt Instrument [Line Items]
Long-term debt			$ 893,400,000				912,600,000
Interest rate of debt instrument	2.50%	2.50%	2.50%	2.50%
Debt instrument, face value \| €				€ 800.0				800.0
Senior notes \| 3.35% senior unsecured notes due 2025
Debt Instrument [Line Items]
Long-term debt			$ 496,900,000				496,800,000
Interest rate of debt instrument	3.35%	3.35%	3.35%	3.35%
Senior notes \| 0.3% senior unsecured notes due 2027
Debt Instrument [Line Items]
Long-term debt			$ 276,900,000				279,900,000
Interest rate of debt instrument	0.30%	0.30%	0.30%	0.30%
Debt instrument, face value \| ¥		¥ 30.8				30.8
Senior notes \| 1.2% senior unsecured notes due 2027
Debt Instrument [Line Items]
Long-term debt			$ 667,600,000				682,000,000
Interest rate of debt instrument	1.20%	1.20%	1.20%	1.20%
Debt instrument, face value \| €				€ 600.0				€ 600.0
Senior notes \| 0.65% senior unsecured notes due 2032
Debt Instrument [Line Items]
Long-term debt			$ 478,100,000				483,400,000
Interest rate of debt instrument	0.65%	0.65%	0.65%	0.65%
Debt instrument, face value \| ¥		¥ 53.2				¥ 53.2
Senior notes \| 4.375% senior unsecured notes due 2045
Debt Instrument [Line Items]
Long-term debt			$ 499,400,000				499,300,000
Interest rate of debt instrument	4.375%	4.375%	4.375%	4.375%
Convertible debt \| Zero-coupon LYONs due 2021
Debt Instrument [Line Items]
Long-term debt			$ 44,300,000				56,200,000
Interest rate of debt instrument	0.00%	0.00%	0.00%	0.00%
Bonds \| 0.5% senior unsecured bonds due 2023
Debt Instrument [Line Items]
Long-term debt			$ 543,400,000				550,700,000
Interest rate of debt instrument	0.50%	0.50%	0.50%	0.50%
Debt instrument, face value \| SFr	SFr 540.0				SFr 540.0
Bonds \| 1.125% senior unsecured bonds due 2028
Debt Instrument [Line Items]
Long-term debt			$ 215,200,000				$ 218,100,000
Interest rate of debt instrument	1.125%	1.125%	1.125%	1.125%
Debt instrument, face value \| SFr	SFr 210.0				SFr 210.0

Hedging Transactions And Derivative Financial Instruments (Narrative) (Details) - Net investment hedging - USD ($) $ in Millions	Mar. 29, 2019	Jan. 31, 2019
Derivative [Line Items]
Derivative, notional amount	$ 9,393.3
Foreign currency contracts
Derivative [Line Items]
Derivative, notional amount	$ 1,875.0	$ 1,900.0

Hedging Transactions And Derivative Financial Instruments (Summary of Notional Values and Pretax Impact in Fair Values of Net Investment Hedges) (Details) - Net investment hedging - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2019	Jan. 31, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Notional Amount	$ 9,393.3
Gain (Loss) Recognized in OCI	152.6
Foreign currency contracts
Derivative Instruments, Gain (Loss) [Line Items]
Notional Amount	1,875.0	$ 1,900.0
Gain (Loss) Recognized in OCI	14.8
Foreign currency denominated debt
Derivative Instruments, Gain (Loss) [Line Items]
Notional Amount	7,518.3
Gain (Loss) Recognized in OCI	$ 137.8

Hedging Transactions And Derivative Financial Instruments (Derivative and Nonderivative Debt Instruments) (Details) - Net investment hedging $ in Millions	Mar. 29, 2019 USD ($)
Prepaid expenses and other current assets
Derivatives, Fair Value [Line Items]
Derivative assets	$ 17.1
Accrued expenses and other liabilities
Derivatives, Fair Value [Line Items]
Derivative liabilities	2.3
Long-term debt
Derivatives, Fair Value [Line Items]
Nonderivative hedging instruments	$ 7,518.3

Defined Benefit Plans (Narrative) (Details) - Defined benefit pension plans $ in Millions	Mar. 29, 2019 USD ($)
Domestic plan \| U.S. pension benefits
Defined Benefit Plan Disclosure [Line Items]
Expected future employer contributions, current fiscal year	$ 10
Non-U.S. pension benefits
Defined Benefit Plan Disclosure [Line Items]
Expected future employer contributions, current fiscal year	$ 50

Defined Benefit Plans (Components of Net Periodic Benefit Cost of Defined Benefit Pension Pans) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2019	Mar. 30, 2018
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ (9.8)	$ (10.9)
Net periodic benefit cost	(4.6)	(3.1)
Defined benefit pension plans \| Domestic plan \| U.S. pension benefits
Defined Benefit Plan Disclosure [Line Items]
Service cost	(1.6)	(2.1)
Interest cost	(22.3)	(20.2)
Expected return on plan assets	31.6	33.1
Amortization of actuarial (gain) loss	(6.3)	(7.8)
Amortization of prior service (cost) credit	(0.2)	(0.3)
Net periodic benefit cost	1.2	2.7
Defined benefit pension plans \| Non-U.S. pension benefits
Defined Benefit Plan Disclosure [Line Items]
Service cost	(8.1)	(8.7)
Interest cost	(6.7)	(6.7)
Expected return on plan assets	10.9	12.1
Amortization of actuarial (gain) loss	0.1	(1.5)
Amortization of prior service (cost) credit	(1.2)	0.1
Settlement loss recognized	0.0	(0.4)
Net periodic benefit cost	$ (5.0)	$ (5.1)

Defined Benefit Plans (Components of Net Periodic Benefit Cost of Other Postretirement Benefit Pension Pans) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2019	Mar. 30, 2018
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ (9.8)	$ (10.9)
Net periodic benefit cost	(4.6)	(3.1)
Other postretirement benefit plans
Defined Benefit Plan Disclosure [Line Items]
Service cost	(0.1)	(0.1)
Interest cost	(1.2)	(1.2)
Amortization of prior service (cost) credit	0.5	0.6
Net periodic benefit cost	$ (0.8)	$ (0.7)

Defined Benefit Plans (Components of Net Periodic Benefit Cost Reflected in the Consolidated Condensed Statement of Earnings) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2019	Mar. 30, 2018
Defined Benefit Plan Disclosure [Line Items]
Total service cost	$ (9.8)	$ (10.9)
Other income, net	5.2	7.8
Net periodic benefit cost	(4.6)	(3.1)
Cost of sales
Defined Benefit Plan Disclosure [Line Items]
Total service cost	(2.0)	(2.1)
Selling, general and administrative expenses
Defined Benefit Plan Disclosure [Line Items]
Total service cost	$ (7.8)	$ (8.8)

Income Taxes (Narrative) (Details) $ / shares in Units, kr in Millions, $ in Millions			3 Months Ended	12 Months Ended		36 Months Ended	48 Months Ended
	Mar. 29, 2019 USD ($)	Dec. 31, 2017	Mar. 29, 2019 USD ($) $ / shares	Dec. 31, 2018	Dec. 21, 2017	Dec. 31, 2012 DKK (kr)	Dec. 31, 2015 USD ($)	Dec. 10, 2013 DKK (kr)
Income Tax Examination [Line Items]
Federal statutory income tax rate, percent		21.00%	21.00%	21.00%	35.00%
Net discrete tax charges, impact, amount			$ 242
Net discrete tax charges, impact, per diluted share \| $ / shares			$ 0.34
Net discrete tax charges, impact, percent			34.00%
Income tax examination, proposed adjustments to taxable income							$ 2,700
Foreign tax authority
Income Tax Examination [Line Items]
Income tax examination, amount of tax assessments	$ 253		$ 253					kr 1,700
Income tax examination, amount of potential additional tax assessments	$ 149					kr 994

Income Taxes (Summary Of Danaher's Effective Income Tax Rate) (Details)	3 Months Ended
	Mar. 29, 2019	Mar. 30, 2018
Income Tax Disclosure [Abstract]
Effective tax rate	53.70%	20.50%

Nonoperating Income (Expense) (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2019	Mar. 30, 2018
Other Income and Expenses [Abstract]
Other income, net	$ 5.2	$ 7.8

Commitments And Contingencies (Narrative) (Details) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 29, 2019 USD ($) $ / shares
Commitments and Contingencies Disclosure [Abstract]
Loss contingency accrual, period increase	$ 36
Loss contingency accrual, period increase, after-tax	$ 29
Loss contingency accrual, period increase, per diluted share \| $ / shares	$ 0.04

Commitments And Contingencies (Warranty Accrual) (Details) $ in Millions	3 Months Ended
	Mar. 29, 2019 USD ($)
Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward]
December 31, 2018	$ 77.4
Accruals for warranties issued during the period	18.0
Settlements made	(17.2)
Effect of foreign currency translation	(0.2)
March 29, 2019	$ 78.0

Stock Transactions And Stock-Based Compensation (Narrative) (Details) $ / shares in Units, $ in Millions			3 Months Ended
	Mar. 29, 2019 USD ($) shares	Mar. 01, 2019 USD ($) $ / shares shares	Mar. 29, 2019 USD ($) shares	Mar. 30, 2018 USD ($)	Apr. 15, 2022 shares	Jul. 16, 2013 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock repurchase program, authorized shares to be repurchased, shares \| shares						20,000,000
Stock repurchase program, remaining number of shares authorized to be repurchased, shares \| shares	20,000,000		20,000,000
Common stock, proceeds from issuance \| $			$ 1,443.2	$ 0.0
Preferred stock, proceeds from the issuance \| $			$ 1,599.6	$ 0.0
Common shares reserved for issuance under the 2007 Omnibus Incentive Plan, shares \| shares	48,000,000		48,000,000
Restricted stock units (“RSUs”)/performance stock units (“PSUs”)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost \| $	$ 246.0		$ 246.0
Weighted average period for cost to be recognized	3 years
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost \| $	$ 209.0		$ 209.0
Weighted average period for cost to be recognized	3 years
Common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of stock, shares \| shares		12,100,000	12,100,000
Common stock issued, price per share \| $ / shares		$ 123.00
Common stock, proceeds from issuance \| $		$ 1,400.0
Payments of stock issuance costs \| $		45.0
Preferred stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of stock, shares \| shares			1,700,000
Payments of stock issuance costs \| $		$ 50.0
Preferred stock, shares issued \| shares		1,650,000
Preferred stock, dividend rate, percent		4.75%
Preferred stock, liquidation preference per share \| $ / shares		$ 1,000
Preferred stock, proceeds from the issuance \| $		$ 1,600.0
Convertible preferred stock, threshold consecutive trading days		20
Preferred stock, annual liquidation preference, per share \| $ / shares		$ 47.50
Preferred stock \| Scenario, forecast \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Convertible preferred stock, shares issued upon conversion \| shares					6.6368
Preferred stock \| Scenario, forecast \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Convertible preferred stock, shares issued upon conversion \| shares					8.1300

Stock Transactions And Stock-Based Compensation (Components of Stock-Based Compensation Program) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2019	Mar. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Pretax compensation expense	$ 39.2	$ 33.3
Income tax benefit	(8.3)	(7.0)
Stock-based compensation expense, net of income taxes	30.9	26.3
Restricted stock units (“RSUs”)/performance stock units (“PSUs”)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Pretax compensation expense	24.3	20.9
Income tax benefit	(5.1)	(4.4)
Stock-based compensation expense, net of income taxes	19.2	16.5
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Pretax compensation expense	14.9	12.4
Income tax benefit	(3.2)	(2.6)
Stock-based compensation expense, net of income taxes	$ 11.7	$ 9.8

Net Earnings Per Share (Narrative) (Details) - shares shares in Millions	3 Months Ended
	Mar. 29, 2019	Mar. 30, 2018
Common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	0.0	3.0
Preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	12.9

Net Earnings Per Share (Components of Basic and Diluted Earnings per Share) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Mar. 29, 2019	Mar. 30, 2018
Numerator
Net earnings	$ 333.8	$ 566.6
Adjustment for interest on convertible debentures	0.5	0.6
MCPS dividends	(6.5)	0.0
Net earnings attributable to common stockholders after assumed conversions for diluted EPS	$ 327.8	$ 567.2
Denominator
Weighted average common shares outstanding used in basic EPS	707.6	698.6
Incremental common shares from assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs	8.7	8.3
Incremental common shares from assumed conversion of the convertible debentures	2.2	2.6
Weighted average common shares outstanding used in diluted EPS	718.5	709.5
Basic EPS	$ 0.46	$ 0.81
Diluted EPS	$ 0.46	$ 0.80

Segment Information (Narrative) (Details)	3 Months Ended
Segment Information (Narrative) (Details)	Mar. 29, 2019 Business_Segments
Segment Reporting [Abstract]
Number of segments reported	4

Segment Information (Segment Results) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2019	Mar. 30, 2018	Dec. 31, 2018
Segment Reporting Information [Line Items]
Sales	$ 4,879.9	$ 4,695.4
Operating profit	723.8	743.0
Identifiable assets	51,774.4		$ 47,832.5
Other
Segment Reporting Information [Line Items]
Operating profit	(111.1)	(54.4)
Identifiable assets	4,203.6		1,144.4
Life Sciences \| Operating segments
Segment Reporting Information [Line Items]
Sales	1,626.9	1,476.0
Operating profit	309.0	271.3
Identifiable assets	22,485.9		22,122.4
Diagnostics \| Operating segments
Segment Reporting Information [Line Items]
Sales	1,536.8	1,519.7
Operating profit	233.1	248.0
Identifiable assets	14,282.8		14,031.1
Dental \| Operating segments
Segment Reporting Information [Line Items]
Sales	659.7	672.6
Operating profit	48.2	50.9
Identifiable assets	6,019.5		5,897.3
Environmental & Applied Solutions \| Operating segments
Segment Reporting Information [Line Items]
Sales	1,056.5	1,027.1
Operating profit	244.6	$ 227.2
Identifiable assets	$ 4,782.6		$ 4,637.3